

Author Index

- Agarwal P, *see* Singh, 763
- Ahmed S. Sudden hypothyroidism and amiodarone-lithium combination: an interaction, 827
- Ahmad S, *see* Singh, 763
- Aidonitis I, Brachmann J, Rizos I, Zacharoulis A, Stavridis I, Toutouzas P, Kübler W. Electropharmacology of the bradycardic agents alinidine and zatebradine (UL-FS 49) in a conscious canine ventricular arrhythmia model of permanent coronary artery occlusion, 555
- Alcocer L, Campos C, Bahena JH, Nacaud A, Parra Carillo J, Calvo C, Weber C, Lerebours C, Mickalonis L, Villahermosa MT. Clinical acceptability of ACE inhibitor therapy in mild to moderate hypertension, a comparison between perindopril and enalapril, 431
- Alexander RW. Investigative developments in atherosclerosis: introduction, 9
- Alexander RW, *see* Treasure, 13
- Amtorp O, *see* Gundersen, 589
- Anjorin FI, *see* Obatomi, 407
- Annable L, *see* Klinke, 319
- Ardia A, *see* Simoni, 347
- Asanoi H, Sasayama S, Sakurai T, Lee J-D, Kinoshita M, Ishimura T, Yoshikawa J-I, Mitsudo K, Sato H, Moriooka S, Nobuyoshi M, Yasue H, the investigators of the Dopexamine Multicenter Study. Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicenter, double-blind, placebo-controlled withdrawal study, 791
- Babini R, du Souich P. Furosemide dynamics in conscious rabbits: modulation by arginine vasopressin, 305
- Bahena JH, *see* Alcocer, 431
- Baiardi A, *see* Simoni, 347
- Baird M, *see* Klinke, 319
- Bartels GL, Remme WJ, den Hartog FR, Wielenga RP, Kruijsen DACM. Additional antiischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy, 749
- Baumbach A, Braun U, Döring G, Haase KH, Voelker W, Karsch KR. Hemodynamics, left ventricular function, and myocardial contractility, 213
- Baxter GF. Animal models in cardiovascular research (2nd revised edition) by David R. Gross, 833
- Becker RC. Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases, edited by H. Bounameaux and M. Dekker, 633
- Begum R, *see* Singh, 763
- Behar S, *see* Leor, 609
- Behar S and the SPRINT Study Group, *see* Leor, 723
- Bellows SD, Hale SL, Simkhovich BZ, Kay GL, Kloner RA. Do antioxidant vitamins reduce infarct size following acute myocardial ischemia/reperfusion? 117
- Belz GG. Elastic properties and windkessel function of the human aorta, 73
- Beranek JT. Preventive treatment of postinfarction heart rupture, 169
- Bergfeldt L, *see* Kennebäck, 709
- Bergfeldt L, *see* Nowinski, 573
- Berwing K, *see* Schlepper, 203
- Beyer ME, *see* Hoffmeister, 351
- Beyerle A, *see* Lehmann, 339
- Bhattacharya S, Jordan R, Machin S, Senior R, Mackie I, Smith CR, Schauble TF, Weisman HF, Lahiri A. Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): potent dose-dependent inhibition of platelet function, 665
- Billing E, *see* Rehnqvist, 493
- Bionda A, *see* Sampietro, 785
- Björkander I, *see* Rehnqvist, 493
- Bochkov VN, *see* Hahn, 815
- Borggreffe M, *see* Haverkamp, 195
- Boulet AP, *see* Klinke, 319
- Boulet AP, *see* Ruddy, 799
- Boulet AP for the Canadian Multicenter Diltiazem-CD Hypertension Trial Group, *see* Ruddy, 413
- Boyko V, *see* Leor, 609, 723
- Brachmann J, *see* Aidonidis, 555
- Braun U, *see* Baumbach, 213
- Breithardt G, *see* Haverkamp, 195
- Bru P, Cointe R, Paganelli F, Ricard P, Lévy S. Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias, 85
- Bucca V, *see* Di Pasquale, 359, 831
- Bunting S, *see* Yang, 125
- Buser PT, Wu ST, Parmley WW, Jasmin G, Wikman-Coffelt J. Distinct modulation of myocardial performance, energy metabolism, and $[Ca^{2+}]_i$ transients by positive inotropic drugs in normal and severely failing hamster hearts, 151
- Calvo C, *see* Alcocer, 431
- Campbell R, *see* Opie, 477
- Campbell RWF. Coadministration of calcium antagonists and ACE inhibitors—is a skeptic convinced? a personal view, 525
- Campos C, *see* Alcocer, 431
- Capone L, *see* Cecchi, 773
- Caracausi R, *see* Di Pasquale, 359
- Carlsson J, *see* Kuhn, 595
- Cavero I, Djellas Y, Guillon J-M. Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels, 245
- Cecchi E, Capone L, Ruocco C, Fazzini A, Mugelli A, Giotti A, Faili P. Iloprost antagonizes the increase in internal calcium concentration induced by alpha-thrombin in human platelets: a study of desensitization, 773
- Chang P, *see* Pitt, 693
- Cheglakov IB, *see* Hahn, 815
- Chen M-F, Yang C-Y, Chen W-Y, Lee C-M, Wu C-C, Liao C-S, Lee Y-T. A doubleblind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension, 401
- Chen W-Y, *see* Chen, 401
- Cheng C-P, *see* Little, 657
- Chockalingam A, *see* Ruddy, 413, 799
- Civalleri D, *see* Simoni, 347
- Clark RG, *see* Yang, 125
- Clozel J-P, *see* Hahn, 815
- Cohn JN. New concepts regarding events that lead to end-stage heart disease, 489
- Cointe R, *see* Bru, 85
- Danne O, *see* Stork, 533
- Darmon J-Y, *see* Witchitz, 237
- den Hartog FR, *see* Bartels, 749
- De Simone G, *see* Ferrara, 459
- Di Pasquale P, Paterna S, Parrinello G, Bucca V, Caracausi R, Pipitone F, Licata G. Effects of captopril on plasma endothelin-1 during thrombolysis: preliminary findings, 359
- Di Pasquale P, Paterna S, Parrinello G, Bucca V, Pipitone F, Tricoli G, Licata G. Does plasma endothelin during thrombolysis depend on infarct size? A pilot study, 831
- Djellas Y, *see* Cavero, 245

- Dobs AS, Prasad M, Goldberg A, Guccione M, Hoover DR. Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs, 677
- Doods HN, *see* van Zwieten, 159
- Döring G, *see* Baumbach, 213
- D'Orta G, *see* Ferrara, 459
- Dumont L, *see* Giasson, 685
- Duraković Z. An increase of plasma digoxin levels after withdrawal from therapy in an elderly patient, 829
- Düren DR, *see* Koch, 437
- du Souich P, *see* Babini, 305
- du Souich P, *see* Homsy, 311
- Eber B, Schumacher M, Tatzber F, Kaufmann P, Luha O, Esterbauer H, Gasser R, Klein W. Evaluation of neopterin as a marker for restenosis following percutaneous transluminal coronary angioplasty, 361
- Edwards G, Weston AH. Pharmacology of the potassium channel openers, 185
- Eichstädt H, *see* Stork, 533
- Elvelin L, *see* Little, 657
- Eriksson SV, *see* Rehnqvist, 493
- Esterbauer H, *see* Eber, 361
- Euler DE. Effect of magnesium on ischemic and reperfusion arrhythmias in a canine model with diminished collateral blood flow, 565
- Faili P, *see* Cecchi, 773
- Fazzini A, *see* Cecchi, 773
- Ferrara LA, De Simone G, Iannuzzi R, Gaeta I, D'Orta G, Turco S, Guida L, Marotta T. Metabolic effects of isradipine in non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients, 459
- Fischer L, *see* Ruddy, 799
- Fisher Hansen J. ACE inhibitors and calcium antagonists in the treatment of congestive heart failure, 503
- Folts JD. Drugs for the prevention of coronary thrombosis: from an animal model to clinical trials, 31
- Forslund L, *see* Rehnqvist, 493
- Fox K, *see* Knight, 229
- Frei U, *see* Stork, 533
- Fujita H, *see* Yamabe, 755
- Fukui T, *see* Saito, 257
- Furuno I, *see* Tsutsumi, 715
- Gaeta I, *see* Ferrara, 459
- Galetta F, *see* Sampietro, 785
- Garceau D, *see* Giasson, 685
- Gasser R, *see* Eber, 361
- Genade S, *see* Moolman, 103
- Ghosh S, *see* Singh, 763
- Gianotti A, *see* Simoni, 347
- Giasson S, Garceau D, Homsy W, Dumont L. Pharmacodynamics and pharmacokinetics of clentiazem and diltiazem in closed-chest anesthetized dogs, 685
- Gillett N, *see* Yang, 125
- Giotti A, *see* Cecchi, 773
- Goldberg A, *see* Dobs, 677
- Goldbourt U, *see* Leor, 609, 723
- Grünberg B, *see* Negrescu, 619
- Guccione M, *see* Dobs, 677
- Guida L, *see* Ferrara, 459
- Guillon J-M, *see* Caverio, 245
- Gundermann K-J, *see* Klimov, 779
- Gundersen T, Wiklund I, Swedberg K, Amtorp O, Remes J, Nilsson B on behalf of the Ramipril Study Group. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo controlled trial, 589
- Guttmann I, *see* Scheufler, 545
- Gwathmey JK, Liao R, Helm PA, Thai-ananthan G, Hajjar RJ. Is contractility depressed in the failing human heart? 581
- Haase KH, *see* Baumbach, 213
- Hahn M, Tkachuk VA, Bochkov VN, Cheglakov IB, Clozel J-P. Blockade of receptor operated calcium channels by mibefradil (Ro 40-5967): effects of intracellular calcium and platelet aggregation, 815
- Hajjar RJ, *see* Gwathmey, 581
- Hale SL, *see* Bellows, 117
- Handa SP, *see* Ruddy, 413, 799
- Harper IS, *see* Moolman, 103
- Harrison DG. Alterations of vasomotor regulation in atherosclerosis, 55
- Hasegawa S, Nakano M, Taniguchi Y, Imai S, Murata K, Suzuki T. The effects of Na⁺-H⁺ exchange blocker amiloride on left ventricular remodeling after anterior myocardial infarction in rats, 823
- Hashimoto K, *see* Motomura, 445
- Haverkamp W, Borggrefe M, Breithardt G. Electrophysiologic effects of potassium channel openers, 195
- Held C, *see* Rehnqvist, 493
- Helm PA, *see* Gwathmey, 581
- Hibiya K, *see* Saito, 257
- Hjemdahl P, *see* Rehnqvist, 493
- Hoeks AP, *see* Kool, 331
- Hoffmeister HM, Beyer ME, Seipel L. Effects of the Na⁺ antagonist cibenzoline on left ventricular function of postischemic hearts, 351
- Homsy W, Marleau S, du Souich P. Furosemide dynamics in conscious rabbits: modulation by angiotensin II, 311
- Homsy W, *see* Giasson, 685
- Honye J, *see* Saito, 257
- Hoover DR, *see* Dobs, 677
- Hoshino T, *see* Sakata, 601
- Iannuzzi R, *see* Ferrara, 459
- Imai S, *see* Hasegawa, 823
- Imai S, *see* Takahashi, 809
- The Investigators of the Dopexamine Multicenter Study, *see* Asanoi, 791
- Ishihata F, *see* Saito, 257
- Ishimura T, *see* Asanoi, 791
- Iwahashi M, *see* Yamabe, 755
- Izumi T, *see* Koyama, 701
- Jasmin G, *see* Buser, 151
- Jenkins DP, Steare SE, Yellon DM. Preconditioning the human myocardium: recent advances and aspirations for the development of a new means of cardioprotection in clinical practice, 739
- Jigam AA, *see* Obatomi, 407
- Jin H, *see* Yang, 125
- Jordan R, *see* Bhattacharya, 665
- Julian DG. Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials? 495
- Juneau M, *see* Klinker, 319
- Kaburagi T, *see* Sakata, 601
- Kamata T, *see* Saito, 257
- Kanmatsuse K, *see* Saito, 257
- Kanda T, *see* Takahashi, 809
- Kaplinsky E, *see* Leor, 609, 723
- Karsch KR, *see* Baumbach, 213
- Kaski JC. Management of vasospastic angina: role of nicorandil, 221
- Kaufmann P, *see* Eber, 361
- Kay GL, *see* Bellows, 117
- Kenneback G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects, 709
- Kim S, *see* Yamabe, 755
- Kinoshita M, *see* Asanoi, 791
- Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study, 141
- Klein W, *see* Eber, 361
- Kleinert HD. Renin inhibition, 645
- Klimov AN, Konstantinov VO, Lipovetsky BM, Kuznetsov AS, Lozovsky VT, Trufanov VF, Plavinsky SL, Gundermann K-J, Schumacher R. "Essential" phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease, 779
- Klinker WP, Baird M, Juneau M, Walters

- D, Warnica W, Lakhani Z, Annable L, Boulet AP, Larivière L. Antiangi-nal efficacy and safety of controlled-delivery diltiazem QD versus an equivalent dose of immediate-release diltiazem TID, 319
- Kloner RA, *see* Bellows, 117
- Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease—overview of clinical efficacy of nicorandil, 229
- Kobayashi I, *see* Takahashi, 809
- Koch KT, Düren DR, van Zwieten PA. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction, 437
- Kodama M, *see* Koyama, 701
- Kolettis TM, *see* Kyriakides, 289
- Konstantinov VO, *see* Klimov, 779
- Kool MJ, Spek JJ, Struyker Boudier HA, Hoeks AP, Reneman RS, van Herwaarden RH, van Bortel LM. Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers, 331
- Kouremetis MT, *see* Vyssoulis, 133
- Koyama S, Kodama M, Izumi T, Shibata A. Experimental rat model representing both acute and chronic heart failure related to autoimmune myocarditis, 701
- Kratzer MAA, *see* Negrescu, 619
- Kremastinos D Th, *see* Kyriakides, 289
- Kruijssen DACM, *see* Bartels, 749
- Kübler W, *see* Aidonidis, 555
- Kuhn A, Carlsson J, Miketic S, Tebbe U. Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina, 595
- Kummerow FA, *see* Singh, 763
- Kuznetsov AS, *see* Klimov, 779
- Kyriakides ZS, Papaioannou G, Paraskeva-aidis IA, Koletis TM, Kremastinos D Th. Systolic functional response of normal older and younger adult left ventricles to beta-blockade during exercise, 289
- Lahiri A, *see* Bhattacharya, 665
- Lakhani Z, *see* Klinke, 319
- Larivière L, *see* Klinke, 319
- Lee C-M, *see* Chen, 401
- Lee J-D, *see* Asanoi, 791
- Lee Y-T, *see* Chen, 401
- Lehmann G, Reiniger G, Wolf H, Bey-erle A, Rudolph W. Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration, 339
- Leor J, Goldbourt U, Behar S, Boyko V, Reicher-Reiss H, Kaplinsky E, Rabinowitz B, the SPRINT Study Group. Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk, 609
- Leor J, Goldbourt U, Rabinowitz B, Reicher-Reiss H, Boyko V, Kaplinsky E, Behar S and the SPRINT Study Group. Digoxin and increased mortality among patients recovering from a acute myocardial infarction: importance of digoxin use, 723
- Lerebours C, *see* Alcocer, 431
- Lévy S, *see* Bru, 85
- Liao R, *see* Gwathmey, 581
- Liau C-S, *see* Chen, 401
- Licata G, *see* Di Pasquale, 359, 831
- Lijnen P. Alterations in sodium metabolism as an etiological model for hypertension, 377
- Lijnen P. Antoon KPC Amery—editorial board member from 1990 to 1994, 375
- Lipovetsky BM, *see* Klimov, 779
- Little WC, Cheng C-P, Elvelin L, Nordlander M. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine, 657
- Lloyd MC, *see* Traub, 421
- Lochner A, *see* Moolman, 103
- Lorenz R, *see* Negrescu, 619
- Lozovsky VT, *see* Klimov, 779
- Luha O, *see* Eber, 361
- Lund-Johansen P. Heretical report on the efficacy of blood pressure treatment in a population setting, 373
- Lüscher TF, Wenzel RR, Moreau P, Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases, 509
- Machin S, *see* Bhattacharya, 665
- Mackie I, *see* Bhattacharya, 665
- Maeda K, *see* Yamabe, 755
- Malmiemi K. Association between serum lipids, glucose tolerance and insulin sensitivity during 12 months of celiprolol treatment, 295
- Marchetti A, *see* Oneglia, 631
- Marleau S, *see* Homsy, 311
- Marotta T, *see* Ferrara, 459
- Mason RP. Differential effect of cholesterol on membrane interaction of charged versus uncharged 1,4-dihydropyridine calcium channel antagonists: a biophysical analysis, 45
- Michaelides AP, *see* Vyssoulis, 133
- Mickalonis L, *see* Alcocer, 431
- Miketic S, *see* Kuhn, 595
- Mitamura H, *see* Tsutsumi, 715
- Mitrovic V, *see* Schlepper, 203
- Mitsudo K, *see* Asanoi, 791
- Mizumura T, *see* Saito, 257
- Möckel M, *see* Stork, 533
- Mogbo SCJ, *see* Obatomi, 407
- Moolman J, Genade S, Winterbach R, Harper IS, Williams K, Lochner A. Preconditioning with a single short episode of global ischemia in the isolated working rat heart: effect on structure, mechanical function, and energy metabolism for various durations of sustained global ischemia, 103
- Moreau P, *see* Lüscher, 509
- Morioka S, *see* Asanoi, 791
- Moriuchi M, *see* Saito, 257
- Motomura S, Hashimoto K. Interactions of a new beta-blocker, celiprolol, with the calcium antagonists, diltiazem and nifedipine, on atrioventricular conduction, 445
- Mozes A, *see* Scheufler, 545
- Mugelli A, *see* Cecchi, 773
- Murata K, *see* Hasegawa, 823
- Murata K, *see* Takahashi, 809
- Nacaud A, *see* Alcocer, 431
- Nakakimura H, *see* Saito, 257
- Nakano M, *see* Hasegawa, 823
- Namura H, *see* Yamabe, 755
- Nayler WG. Atherosclerosis and endothelial damage: a brief overview, 25
- Negrescu EV, Grünberg B, Kratzer MAA, Lorenz R, Siess W. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside, 619
- Niaz AM, *see* Singh, 763
- Nilsson B on behalf of the Ramipril Study Group, *see* Gundersen, 589
- Nobuyoshi M, *see* Asanoi, 791
- Nordlander M, *see* Little, 657
- Nowinski K, Bergfeldt L. "Normal" response of the QT interval and QT dispersion following intravenous injection of the sodium channel blocker disopyramide: methodological aspects, 573
- Obatomi DK, Mogbo SCJ, Anjorin FI, Jigam AA. Changes in urinary enzyme levels following the use of anti-hypertensive agents in patients with essential hypertension, 407
- Ogawa S, *see* Tsutsumi, 715
- Okada Y, *see* Tsutsumi, 715
- Olsson G, *see* Panfilov, 273
- Oneglia C, Marchetti A, Rusconi C. Methylergometrine-induced myo-

- cardiac ischemia in a previously asymptomatic premenopausal woman, 631
- Onouchi Z, *see* Singh, 763
- Opie L, Campbell R. Introduction, 477
- Opie LH. Clinical hypertension 6th edition, by N. Kaplan, 363
- Opie LH. The ECG workbook: a review and discussion of ECG findings and abnormalities by Glenn N, Levine and Philip J. Podrid, 835
- Opie LH. New concepts regarding events that lead to myocardial infarction, 479
- Opie LH. Review of "Cardiovascular pharmacology and therapeutics" by Singh et al., 171
- Osawa K, *see* Saito, 257
- Osawa Y, *see* Saito, 257
- Paganelli F, *see* Bru, 85
- Panfilov V, Wahlqvist I, Olsson G. The use of beta-adrenoceptor blockers in patients with congestive heart failure, 273
- Papaioannou G, *see* Kyriakides, 289
- Papazachariou GS, *see* Kirpizidis, 141
- Paraskevaidis IA, *see* Kyriakides, 289
- Parmley WW, *see* Buser, 151
- Parra Carillo J, *see* Alcocer, 431
- Parrinello G, *see* Di Pasquale, 359, 831
- Paterna S, *see* Di Pasquale, 359, 831
- Pipitone F, *see* Di Pasquale, 359, 831
- Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy, 145
- Pitt B. Role of calcium channel blocking agents in the prevention of atherosclerosis, 21
- Pitt B, Chang P, Timmermans P. Angiotensin II receptor antagonists in heart failure: rationale and design of the Evaluation of Losartan in the Elderly (ELITE) trial, 693
- Plavinsky SL, *see* Klimov, 779
- Frasad M, *see* Dobs, 677
- Purcell H, *see* Knight, 229
- Rabinowitz B, *see* Leor, 609, 723
- Rehnqvist N, Hjerdahl P, Björkander I, Eriksson SV, Forslund L, Held C, Wallen H, Billing E. Primary prevention in patients with coronary heart disease: the APSIS study, 493
- Reicher-Reiss H, *see* Leor, 609, 723
- Reiniger G, *see* Lehmann, 339
- Remes J, *see* Gundersen, 589
- Remme WJ, *see* Bartels, 749
- Reneman RS, *see* Kool, 331
- Ricard P, *see* Bru, 85
- Rizos I, *see* Aidonidis, 555
- Ruddy TD, Wright JM, Savard D, Handa SP, Chockalingam A, Fischer L, Boulet AP. 24 hour blood pressure control with once-daily versus twice-daily formulations of diltiazem, 799
- Ruddy TD, Wright JM, Savard D, Handa SP, Chockalingam A, Boulet AP for the Canadian Multicenter Diltiazem-CD Hypertension Trial Group. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension, 413
- Rudolph W, *see* Lehmann, 339
- Ruocco C, *see* Cecchi, 773
- Rusconi C, *see* Oneglia, 631
- Sadanaga T, *see* Tsutsumi, 715
- Saito S, Mizumura T, Takayama T, Honye J, Fukui T, Kamata T, Moriuchi M, Hibiya K, Tamura Y, Ozawa Y, Kanmatsuse K, Osawa K, Ishihata F, Nakakimura H, Sakai K. Antiischemic effects of nicorandil during coronary angioplasty in humans, 257
- Sakai K, *see* Saito, 257
- Sakata K, Hoshino T, Yoshida H, Kaburagi T, Takada A. Effects of beraprost sodium, a new prostaglandin I₂ analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina, 601
- Sakurai T, *see* Asanoi, 791
- Sampietro T, Galetta F, Bionda A. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin, 785
- Sasayama S, *see* Asanoi, 791
- Sato H, *see* Asanoi, 791
- Savard D, *see* Ruddy, 413, 799
- Schaible TF, *see* Bhattacharya, 665
- Scheufler E, Mozes A, Guttman I, Wilfert B. R56865 is antiarrhythmic in reperfused ischemic guinea pig hearts even when given only during reperfusion, 545
- Schlepper M, Thormann J, Berwing K, Strasser R, Mitrovic V. Effects of nicorandil on regional perfusion and left ventricular function, 203
- Schumacher M, *see* Eber, 361
- Schumacher R, *see* Klimov, 779
- Seipel L, *see* Hoffmeister, 351
- Senior R, *see* Bhattacharya, 665
- Shibata A, *see* Koyama, 701
- Siess W, *see* Negrescu, 619
- Simkhovich BZ, *see* Bellows, 117
- Simoni G, Gianotti A, Ardia A, Baiardi A, Civalieri D. Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol—pilot study, 347
- Singh RB, Niaz AM, Ghosh S, Agarwal P, Ahmad S, Begum R, Onouchi Z, Kummerow FA. Randomized, controlled trial of antioxidant vitamins and cardioprotective diet on hyperlipidemia, oxidative stress, and development of experimental atherosclerosis: the Diet and Antioxidant Trial on Atherosclerosis (DATA), 763
- Smith CR, *see* Bhattacharya, 665
- Spek JJ, *see* Kool, 331
- SPRINT Study Group, *see* Leor, 609
- Stavridis I, *see* Aidonidis, 555
- Stearse SE, *see* Jenkins, 739
- Stork T, Möckel M, Danne O, Völler H, Eichstädt H, Frei U. Left ventricular hypertrophy and diastolic dysfunction: their relation to coronary heart disease, 533
- Strasser R, *see* Schlepper, 203
- Struyker Boudier HA, *see* Kool, 331
- Suzuki T, *see* Hasegawa, 823
- Suzuki T, *see* Takahashi, 809
- Swedberg K, *see* Gundersen, 589
- Takase H, *see* Lüscher, 509
- Takada A, *see* Sakata, 601
- Takahashi T, Kanda T, Imai S, Suzuki T, Kobayashi I, Murata K. Semotidil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension, 809
- Takayama T, *see* Saito, 257
- Tamura Y, *see* Saito, 257
- Taniguchi Y, *see* Hasegawa, 823
- Tatzber F, *see* Eber, 361
- Tebbe U, *see* Kuhn, 595
- Thaiyananthan G, *see* Gwathmey, 581
- Thormann J, *see* Schlepper, 203
- Timmermans P, *see* Pitt, 693
- Tkachuk VA, *see* Hahn, 815
- Tomson T, *see* Kenneback, 709
- Toutouzas P, *see* Aidonidis, 555
- Toutouzas PK, *see* Vysoulis, 133
- Traub O, Lloyd MC, Webb RC. Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats, 421
- Treasure CB, Alexander RW. Relevance of vascular biology to the ischemic syndromes of coronary atherosclerosis, 13
- Tricoli G, *see* Di Pasquale, 831
- Trufanov VF, *see* Klimov, 779
- Tsutsumi N, Mitamura H, Okada Y, Yoshimoto T, Sadanaga T, Furuno I, Ogawa S. Rate-dependent anisotropic conduction property in the epicardial border zone of canine myocardial infarcts and its modification by moricizine, 715
- Turco S, *see* Ferrara, 459

- Valioli MA, *see* Vyssoulis, 133
van Bortel LM, *see* Kool, 331
van Herwaarden RH, *see* Kool, 331
van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine, 159
van Zwieten PA, *see* Koch, 437
Villahermosa MT, *see* Alcocer, 431
Voelker W, *see* Baumbach, 213
Völler H, *see* Stork, 533
Vyssoulis GP, Kouremetis MT, Valioli MA, Michaelides AP, Toutouzas PK. Effect of β -blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol, 133
Wahlqvist I, *see* Panfilov, 273
Wallén H, *see* Rehnqvist, 493
Walters D, *see* Klinke, 319
Warnica W, *see* Klinke, 319
Webb RC, *see* Traub, 421
Weber C, *see* Alcocer, 431
Weisman HF, *see* Bhattacharya, 665
Wenzel RR, *see* Lüscher, 509
Weston AH, *see* Edwards, 185
Wielenga RP, *see* Bartels, 749
Wiklund I, *see* Gundersen, 589
Wikman-Coffelt J, *see* Buser, 151
Wilffert B, *see* Scheufler, 545
Williams K, *see* Moolman, 103
Winterbach R, *see* Moolman, 103
Witchitz S, Darmon J-Y. Nicorandil safety in the long-term treatment of coronary heart disease, 237
Wolf H, *see* Lehmann, 339
Wright JM, *see* Ruddy, 413, 799
Wu C-C, *see* Chen, 401
Wu ST, *see* Buser, 151
Yamabe H, Namura H, Yano T, Fujita H, Kim S, Iwahashi M, Maeda K, Yokoyama M. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise ^{201}Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms, 755
Yang C-Y, *see* Chen, 401
Yang R, Bunting S, Gillett N, Clark RG, Jin H. Effects of growth hormone in rats with post infarction left ventricular dysfunction, 125
Yano T, *see* Yamabe, 755
Yasue H, *see* Asanoi, 791
Yellon DM, *see* Jenkins, 739
Yokoyama M, *see* Yamabe, 755
Yoshida H, *see* Sakata, 601
Yoshikawa J-I, *see* Asanoi, 791
Yoshimoto T, *see* Tsutsumi, 715
Young JB. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials, 89
Zacharoulis A, *see* Aidonidis, 555
Zanchetti A. Vascular complications in hypertension: the VHAS study, 529

Subject Index

- A-64662, 648
A-72517, 648
A-74273, 648-649, 651
Abnormal cation metabolism, sodium metabolism alterations, 377-393
Acebutolol, 135
 for chronic heart failure, 282
 for congestive heart failure, 276, 279
 reducing mortality after reinfarction, 495
ACE genotype (ACE-DD), 97-98
Acenocoumarol, 240, 242
Acetylcholine (ACh), 147, 249, 511, 513, 516, 517
 constricting human coronary arteries, 159, 160, 161, 162, 163
 coronary artery responses, 55-56, 57, 58, 59, 60, 61
Acidosis, intracellular, 198
Acquired long-QT syndromes, 198
Actin-myosin interaction, 585
Action potential duration, 188, 196, 197, 199-200, 246, 253
 carbamazepine, 709-714
Acute heart failure, dioxamine withdrawal study, 791-796
Acute Infarction Ramipril Efficacy (AIRE) Study, 89-93, 95, 100, 145, 463-464, 496, 498
 effects of ramipril, 503-505
Acute myocardial infarction, 9, 10, 146
 ACE inhibitors after, 519-520
 captopril effects on plasma endothelin-1 during thrombolysis, 359-360
 caused by thrombotic occlusion from platelet-initiated events, 34, 35
 d-sotalol study, 441
 management of (book review), 464
 risk factors for, 479-485
Acute myocardial ischemia, 195
Acute posterolateral ischemia, 199
Acute spasms, 164
Acute thrombotic event, 484
Acute transmural myocardial infarction, 34
Adenine nucleotides, 25, 250
Adenosine, 56, 245, 246, 249, 491
Adenosine diphosphate (ADP), 32, 35, 38-39, 198, 245-246, 485, 582
 in ischemic preconditioning in rat heart, 107, 108
 m7E3 Fab markedly inhibiting platelet, 665, 667-670
 mibefradil effects on receptor operated calcium channels inhibited by, 815-820
 positive inotropic therapy for heart failure, 153, 155, 156
Adenosine diphosphate-induced calcium influx, 38
Adenosine 5'-diphosphate, synergistic interaction of antiplatelet drugs, 619-621, 623, 624, 625, 627
Adenosine monophosphate (AMP), 34, 245
 in ischemic preconditioning in rat heart, 107, 108
Adenosine triphosphate (ATP), 34, 245, 247, 253, 491, 582-583
 positive inotropic therapy for heart failure, 152, 153, 155, 156
 synergistic interaction of antiplatelet drugs, 622, 623
 utilization in ischemic preconditioning, 104, 107, 108, 111, 114
Adenosine triphosphate (ATP)-dependent potassium channels (K_{ATP}), 740, 744
Adenosine triphosphate-sensitive potassium channels, 222, 223, 261-262
 nicorandil clinical efficacy, 229, 234-235
 nicorandil safety in coronary heart disease, 237, 242
 openers of, 185-186, 187, 190
 opening of, and ischemic myocardial cell protection, 245-254
 properties, 246-248
Adenosine triphosphate-sensitive potassium current, 187, 195
Adenylate cyclase (AC), 34, 37, 39, 163, 274
Adenyl cyclase, celiprolol and metabolic syndrome, 302
Adaptive hypertrophy, 535
Adrenaline, 274
Adrenergic, ACE inhibitor alteration of genetic hypertension development in rats, 421-429
Adrenocorticotrophic hormone (ACTH), 360, 832
 increased levels stimulating aldosterone production, 146
Adriamycin, 278
Advanced heart block, beta-blockers and, 495
AF-DX 116
 antagonist for muscarinic receptor subtypes, 159-165
 chemical structure, 161
African Americans, 381-382, 383-384, 386-388
Afterdepolarizations, 195, 197-198
Afterload, 96, 97, 207, 210, 535
 heart failure in autoimmune myocarditis, 704
 nicorandil clinical efficacy, 229, 230
 nicorandil's effect on, 224, 257, 261
 reduced after two doses of nicorandil, 213, 214, 219
 reduced by nicorandil, 332, 336
 reduction of, 38
 Windkessel function reduction of, 75-76
Age
 aortic elastic properties affected by, 76
 factor in beta-blocker effects on exercise hypertensives, 138
 plasma membrane cholesterol content, 52
Aggregometry, 31, 32, 35, 39
Aggressive lipid-lowering therapy, 16, 18
AH interval, celiprolol with calcium antagonists on AV conduction, 445-456
Akinesia, regional, 204, 208, 209
Albumin excretion, 520
Alcohol, 290, 710
 nicorandil and ISDN and large arteries, 332
Aldactone, 148
Aldosterone, 490
 coadministered with ACE inhibitors, 428
 "escape" of production in left ventricular dysfunction, 145-148
 furosemide dynamics and angiotensin II, 315
 furosemide dynamics and arginine-vasopressin, 305
 renin inhibition, 651
 with angiotensin II in ELITE trial, 695, 697
Aldosteronism, 147
Alinidine, for myocardial infarction in dogs, 555-562
Alkaline phosphatase (ALP), 407, 408, 409
Allfit computer program, 774, 776
Alpha-adrenergic blockade, 31
Alpha-blockers, 36
Alpha 1 receptor blocker, 490
Alpha 1 subunit, 45
Alpha-thrombin, 773, 774, 775-776
Alpha₂-adrenergic receptors, 36
Alprazolam, 36
Alprenolol, 273
Alzheimer's disease, 163, 165
Amaurosis fugax, 34
Ambulatory blood pressure monitoring (ABPM), diltiazem CD vs. twice-daily, 799-806

- Ambulatory electrocardiogram monitoring, nicorandil effect on variable threshold angina, 225, 226
- Ambulatory electrocardiographic monitoring, 14
- American Heart Association (AHA) Step I diet, 678-679
- Amery, Antoon, in memoriam, 375
- Amiloride, 379
effect on LV remodeling after anterior myocardial infarction in rats, 823-825
- Amino acids, 39
- Amiodarone, 85, 86, 196, 491, 497
associated with several adverse reactions, 437, 438, 439, 441
with lithium for sudden hypothyroidism, 827-828
with nicorandil, 240
- Amiodarone and lithium, sudden hypothyroidism, 827-828
- Amlodipine, 10, 504
effect on sudanophilic lesion formation in rabbit aorta, 28
membrane cholesterol content change effects, 45, 48-49, 51, 52, 53
membrane partition coefficient, 45, 50, 51
preventing atherosclerosis, 21, 23-24
structural formula, 46
vascular selectivity, 657-659, 661
vs. elgodipine, 599
with aspirin, 38
- Amrinone, positive inotropic agents for heart failure, 151, 152, 153, 155, 156
- Analgesics, 92, 240
- Anesthetics, 52
- Aneurysm, d-sotalol study, 439, 441
- Angina pectoris, 13
ACE inhibitors effect on, 95-96
APSYS Study, 493
beta-blockers preferentially useful, 445
diltiazem, controlled-delivery QD vs. immediate-release TID, 319-329
drugs evaluated (book review), 464
elgodipine's hemodynamic effects, 595-600
felodipine for cardiovascular disorders, 657-661
L-propionylcarnitine long-term effects, 749-753
mibefradil therapy, 820
nicorandil and ISDN and large arteries, 331-336
nicorandil as potassium channel opener, 196
nicorandil clinical efficacy, 229-235
nicorandil effects, 204
nicorandil role in management of vasospastic angina, 221-226
nicorandil's antiischemic effects during coronary angioplasty, 257-262
pirenzepine as potential drug target, 165
potassium channel openers, 190
risk factors for, 483
SOLVD study, 91
stable, 14-15, 18, 37
- Angina pectoris and normal coronary angiograms, nicorandil therapy, 755-760
- Angiocardiography, to study aortic elasticity, 79
- Angioedema, 145, 696
- Angioplasty, 34, 35, 40, 499
diltiazem study, 322
- Angiotensin, atherosclerosis and, 517-518
- Angiotensin-converting enzyme (ACE), 25
gene changes, 483
- Angiotensin-converting enzyme (ACE) inhibitors, 73, 80-81, 130, 283, 296, 301, 360
aldosterone production, escape of, 145-148
alteration of genetic hypertension development in rats, 421-429
antiatherogenic effects in animals, 98
chronic effects on endothelial function, 515-517
coadministration with calcium antagonists, 525-527
coprescription with verapamil, 527
digoxin and myocardial infarction, 614
dilated cardiomyopathy, 275, 278
effects on atherosclerosis, 10
effects on regression of left ventricular hypertrophy in hypertensive patients, 141-143
Evaluation of Losartan in the Elderly (ELITE) trial, 693-697
for congestive heart failure treatment, 503-506
for mild to moderate hypertension, 431-436
interactions with aspirin, nitrates, and diuretics, 497
interaction with calcium antagonists in clinical conditions, 518
intervention trials after myocardial infarction, 495, 496, 501
postinfarction heart rupture, 169
ramipril effect on quality of life in CHF trials, 589-593
renin inhibition, 645-653
to reduce ischemic events, 89-100
vascular protective effects, 509-520
with d-sotalol, 439, 441
with verapamil, 506
- Angiotensin-converting enzyme inhibitors (book review), 463
- Angiotensinogen, renin inhibition, 645-653
- Angiotensin I, 645, 646, 695
vascular protective effects of ACE inhibitors and calcium antagonists, 509, 510, 513
- Angiotensin-renin system, ACE inhibitor alteration of genetic hypertension development in rats, 421, 427
- Angiotensin II, 479-480, 483, 485, 490, 491, 832
ACE inhibitor alteration of genetic hypertension development in rats, 421-429
amiloride effects on LV remodeling after anterior myocardial infarction in rats, 825
coronary and cardiac effects, 96-99
endothelin-1 and, 515
enhancing vasoconstriction responses, 359, 360
escape of aldosterone production in left ventricular dysfunction, 145-148
Evaluation of Losartan in the Elderly (ELITE) trial, 693-697
furosemide dynamics and, 311-315
furosemide dynamics and arginine vasopressin, 305
renin inhibition, 645, 646, 649-653
vascular protective effects of ACE inhibitors and calcium antagonists, 509, 510, 513, 515-518
- Angle of insonation, 79
- Animal Models in Cardiovascular Research (book review), 833-834
- Anisotropic conduction, rate-dependent property and moricizine, 715-722
- Anistreplase, 498
- Anoxia, 744
- Antazoline, 185, 190
chemical structure, 189
- Antiarrhythmic agents
digoxin and myocardial infarction, 725-726, 727
d-sotalol and ventricular tachycardia, 437-442
intervention trials after myocardial infarction, 496, 501
- Antiarrhythmic therapy (book review), 463
- Antibodies, generated by oxidized LDL, 16
- Anticholinergic effect, cibenzoline, 87
- Anticholinergics, 164
- Anticoagulants, 36, 92, 242, 602, 604, 605
reducing mortality and reinfarction, 495, 496, 501
- Antidigoxin antibody, 388
- Antihypertensive agents
ACE inhibitor alteration of genetic hypertension development in rats, 421-429
renal enzymuria affected by, 407-411
- Antihypertensive therapy (book review), 463
- Antiinflammatory agents, 18
- Antilipemic agents, gemfibrozil and Mediterranean diet, 347-350
- Antioxidant vitamins, 9, 15, 18, 23, 480, 481
and diet on atherosclerosis, 763-770
infarct reduction following acute myo-

- cardiac ischemia/reperfusion, 117-122
- Antiplatelet agents, 10, 32, 94
- interaction with nitric oxide donors, 619-628
- m7E3 Fab markedly inhibiting platelet aggregation, 665-674
- reducing mortality and reinfarction, 496
- Antithrombin, 25
- Aorta, elastic properties and Windkessel function of, 73-81
- Aortic elastic properties, 73-81
- diagnostic and prognostic implications, 79-80
- therapeutic implications, 80-81
- Apexcardiogram, 275
- Apolipoprotein B-100, 349
- Apoprotein A, 347, 348, 349
- neopterin study, 362
- Apoprotein A1, Lp(a) and simvastatin, 785-788
- Apoprotein B, 347, 348, 349
- Lp(a) and simvastatin, 785-788
- neopterin study, 362
- Apoprotein C2, Lp(a) and simvastatin, 785-788
- Apoprotein C3, Lp(a) and simvastatin, 785-788
- Apoprotein E, Lp(a) and simvastatin, 785-788
- Aprikalim, 187, 189, 195, 262
- chemical structure, 188
- opening ATP-sensitive potassium channels and conferring cardioprotection, 245-254
- Aprindine, 496
- APISIS Study, 493
- AQ-RA 681, 161
- AQ-RA 741
- antagonist for muscarinic receptor subtypes, 160, 161, 162
- chemical structure, 161
- Arachidonic acid (AA), 35, 47, 667
- Area of necrosis (AN), infarct reduction following acute myocardial ischemia/reperfusion, 118, 119, 120, 122
- Arecoline, 160
- Arginine, 39, 55, 56, 58-59
- deficiencies, 58-59
- Arginine-glycine-aspartic acid peptide mimetics, 31
- Arginine vasopressin (AVP)
- furosemide dynamics and angiotensin II, 311, 312, 313, 314-315
- furosemide dynamics in conscious rabbits, 305-309
- Arrhythmias, 34, 491
- beta-blocker treatment for prevention, 274
- digoxin and myocardial infarction, 609-615, 723-728
- d-sotalol influence on, 437-442
- infarct reduction following acute myocardial ischemia/reperfusion, 119
- magnesium and reperfusion arrhythmias, 565-570
- potassium-channel openers' effects, 195-200, 241
- prevented by cardioprotective agents, 245, 252-254
- R56865 and reperfused ischemic hearts, 545-552
- Arrhythmogenesis, 241, 248
- Arterial compliance, nicorandil and isosorbide dinitrate (ISDN), 331-336
- Arterial distensibility, nicorandil and isosorbide dinitrate (ISDN), 331-336
- Arterial hypertension, beta-blocker effects on exercise hypertensives, 133-139
- Arterial lumen, 31, 32
- Arteries, elastic properties and Windkessel function of human aorta, 73-81
- Ascites, 153
- Aspartic acid, 39
- Aspirin, 10, 92, 94, 100, 361
- APISIS Study, 493
- inhibiting platelet activity and abolishing CFRs, 31-33, 35, 38-40
- interaction with ACE inhibitors, 497, 500
- potential problems, 35-36, 37
- preceding m7E3 Fab antibody dose, 666, 670, 672
- reducing mortality and reinfarction, 495, 496, 498, 500, 501
- synergistic interaction of antiplatelet drugs, 619-628
- to prevent cardiovascular disease, 485
- with amlodipine, 38
- with diltiazem, 38
- with dipyridamole, 37-38
- with nitrendipine, 38
- with verapamil, 38
- Asthma, beta-blockers and, 495, 501
- Asymptomatic aortic aneurysms (AAA), 347-350
- Asynchrony, 536
- Atenolol, 138, 296
- adverse reactions, 405
- in ISIS-1 trial, 500
- postinfarction heart rupture, 169
- vs. celiprolol, 454
- vs. controlled-release metoprolol in hypertension, 401-406
- vs. nicorandil, 232, 233
- Atherogenesis, 13
- Atheroma, 525-527
- Atheroma formation, 29
- Atherosclerosis, 13, 15
- ACE activity and, 515
- angiotensin and, 517-518
- aortic elastic properties affected by, 76-77, 80
- biology of, 14
- biology related to coronary ischemic syndromes, 9
- calcium antagonists and, 512-513
- calcium channel blocker role in prevention, 21-24
- cellular mechanisms of impaired vasodilation/enhanced vasoconstriction in atherosclerosis, 15
- coadministration of calcium antagonists and ACE inhibitors, 525-527
- dietary, and cholesterol content in membrane, 46
- diet-induced, 58, 80
- elastic properties and Windkessel function of human aorta, 73-81
- endothelial damage, 25-29
- endothelin and escape of aldosterone production, 147
- investigative developments in, 9-10
- Lp(a), apoproteins, and simvastatin, 785-788
- neopterin as marker for restenosis following PTCA, 361-362
- oxidation hypothesis of, 479
- vasomotor regulation alterations, 55-61
- Verapamil-Hypertension Atherosclerosis Study, 529-530
- Atherosclerotic disease, drugs preventing coronary thrombosis, 31-40
- Atherosclerotic lesion formation, 13
- Atherosclerotic lesions, 10
- Atherosclerotic plaque, 677
- Atherosclerotic vessel wall, 9, 10, 13
- Athlete's heart, 535
- Atomic absorption spectrometry, 547
- Atrial arrhythmias, 197
- Atrial fibrillation, 85, 86, 87
- Atrial flutter, 85, 86, 87
- Atrial natriuretic factor (ANF), 146
- Atrial natriuretic peptide (ANP), 360, 490, 695
- furosemide dynamics and angiotensin II, 312, 313, 314-315
- Atrial premature beats (APBs), 611
- Atrial tachycardia, 85, 86
- Atrioventricular (AV) block, 199, 241, 281, 418
- clinical implications of vascular selectivity, 660
- digoxin and myocardial infarction, 724, 725, 727
- Atrioventricular (AV) conduction
- carbamazepine, cardiac electrophysiological effects of, 709-714
- celiprolol with calcium antagonists on, 445-456
- Atrioventricular (AV) conduction block, celiprolol with Ca antagonists on AV conduction, 445-456
- Atrioventricular (AV) nodal reentry tachycardia, alinidine preventive effect, 562
- Atropine, 80, 161, 162, 163, 164
- carbamazepine, electrophysiological effects, 709, 710, 711, 713
- chemical structure, 161

- Auscultatory post-tussive pulmonary rales, 93
- Australia and New Zealand Heart Failure Research Collaborative Group (ANZ), 280
- Auto-antibodies, 274
- Autoimmune myocarditis, heart failure in rats, 701-706
- Autoimmune thyroid disorders, 828
- Automatic implantable cardioverter defibrillator (AICD), 827-828
- Autoreceptors, 161
- Balanced vasodilation, dopexamine withdrawal study in heart failure, 791-796
- Balloon injury, 14
- Bamiphylline, 742
- Bantu natives of Zaire, 380, 389
- BAPTA, mibefradil effects on receptor operated calcium channels, 815-820
- Barium, 198, 199
- Baroreceptor reflexes, 197
- Baroreflex sensitivity, clentiazem and diltiazem, 690
- Bay K 8644, 198
- Bazett method, 710
- Bazett's formula, 199
- Benazapril, 516
- Benzimidazoles, 187
- Benzofuranisophthalate, 381
- Benzopyrans, 186, 187, 188
- Benzothiazepines, 50, 187, 188, 600
- Bepridil, with nicorandil, 240
- Beraprost sodium, effects on exertional angina, 601-606
- Beta-adrenoceptor antagonists, 81
- Beta-adrenergic blockade, in elderly during exercise, 289-293
- Beta-adrenergic-blocking agent, 22
- Beta-adrenergic receptor blocking agents, 145-146
- Beta-adrenergic receptors, 52
- Beta-adrenoceptor antagonists, celiprolol with calcium antagonists on AV conduction, 445-456
- Beta-adrenoceptor blockers, 491
- in congestive heart failure, 273-283
- Beta-adrenoceptor blocking agents, 401-406
- Beta-adrenoceptors, 163
- Beta₃ adrenergic agonism (book review), 464
- Beta-Blocker Evaluation of Survival Trial (BEST), 280
- Beta-Blocker Heart Attack Trial (BHAT), 90, 94, 281, 500, 614, 615
- Beta-Blocker Pooling Project (BBPP), 614
- Beta-blockers, 22, 92, 94-95, 98-99, 163, 171
- APSYS Study, 493
- causing further haemodynamic deterioration, 437
- celiprolol with calcium antagonists on AV conduction, 445-456
- combination therapy, 282-283
- digoxin and myocardial infarction, 612, 726
- discontinued before nicorandil study, 214
- effect of long-term treatment on patient survival, 280-281
- effects on exercise hypertensives, 133-139
- for angina, 759
- for congestive heart failure, 273-283
- for patients in metoprolol CR/ZOK vs. atenolol study, 401-406
- metabolic syndrome, 295
- neurohormonal and cellular mechanisms of action, 274
- postinfarction heart rupture, 169
- reducing mortality and reinfarction, 495, 496, 498, 500, 501
- short-term vs. long-term effects, 275
- vs. nicorandil clinical efficacy, 231, 232
- vs. nicorandil for coronary heart disease, 237, 239
- vs. potassium channel openers, 196
- withdrawal and readministration of treatment, 280
- with nicorandil, 240
- Beta-carotene, 481, 764, 765, 770
- Bezafibrate, 349
- BIBN 99, antagonist for muscarinic receptor subtypes, 160, 163
- Bile-acid sequestrants, 349
- Bimakalim, 195, 250, 251-252
- Bioenergetics, 489, 491
- Bisoprolol, 280
- for chronic heart failure, 282
- Blacks
- dietary sodium and blood pressure in Africans, 389
- hypertension, untreated, 392
- normotensive, 381-382, 383-384, 386-388
- Blaustein's hypothesis, 391
- Bleb formation, 26
- Blood flow
- nicorandil effect on, 213
- nicorandil role in management of vasospastic angina, 221, 222
- Blood lipid abnormalities, leading to acute myocardial infarction, 479-480
- Blood pressure
- aortic elastic properties affected by, 76
- renin inhibition effects, 648-649, 653
- B-mode ultrasonography, 23
- Body mass index (BMI), 348
- Body weight, growth hormone effects in rats with postinfarction left ventricular dysfunction, 125-130
- Bonferroni method, 449-450, 451, 455
- Bovine cardiac phosphatidylcholine (BCPC) lipids, 47, 49-51
- Brachial artery, 80
- Bradycardia, 198, 235, 438, 451
- alinidine and zatebradine for myocardial infarction in dogs, 555-562
- beta-blocker effects on exercise hypertensives, 138
- carbamazepine, 714
- cibenzoline effect on postischemic hearts, 356
- clinical implications of vascular selectivity, 660
- muscarinic receptor antagonists beneficial for, 159, 163, 164, 165
- Bradycardia-hypotension syndrome, 163
- Bradykinin, 96, 99, 100, 359
- ACE inhibitor alteration of genetic hypertension development in rats, 428
- effects of ACE inhibitors, 693-697
- vascular protection, 510, 513, 515, 516, 518
- Brinerdin, effect on renal enzymuria, 407-411
- BRL 38227. *See* Lemakalim
- Bronchitis, 435
- Bronchoconstriction, 163
- Bronchodilators, 164
- Bucindolol, 280, 281
- for chronic heart failure, 282
- for congestive heart failure, 276, 277, 278, 279
- Bumetanide, 378-379
- Bypass surgery, 262
- diltiazem study, 322
- BW-175, 648
- Caffeine, 290, 710
- nicorandil and ISDN and large arteries, 333
- Calcium, 59
- aldosterone administration effect, 147
- free cytosolic levels in platelets, 34-35, 36, 37, 38
- in failing hearts, 581-586
- intracellular free, 97
- intracellular, positive inotropic therapy for heart failure, 151, 155
- mobilization phase studies, 37-38
- R56865 and reperfused ischemic hearts, 545-552
- role in atherosclerosis development, 21
- uptake by platelets, 36
- Calcium antagonists, 25, 29, 81, 171
- antiatheroma effects of, 525-526
- APSYS Study, 493
- atherosclerosis and, 512-513
- causing further haemodynamic deterioration, 437
- clentiazem, 685-691
- diltiazem, 685-691
- diltiazem controlled delivery QD, 319-329
- elgodipine's hemodynamic effects in chronic stable angina, 595-600
- endothelin and, 511-512
- endothelium and, 28-29

- endothelium-dependent relaxations and, 510-511
for congestive heart failure treatment, 503-506
for Prinzmetal's variant angina, 221, 222
fosinopril vs. nifedipine effects on left ventricular hypertrophy, 141-143
interaction with ACE inhibitors in clinical conditions, 518-520
reducing mortality and reinfarction, 495-496, 497
semotiadil, 809-813
vascular protective effects, 509, 510-513, 514, 517
vs. nicorandil clinical efficacy, 231, 232-233
vs. nicorandil for coronary heart disease, 237, 239
vs. potassium channel openers, 196
with celiprolol, on AV conduction, 445-456
Calcium channel antagonists, 10, 15, 92, 94, 98-100, 247
cholesterol content in membrane, change effects, 45-53
Calcium channel blockers, 10, 94, 296
elgodipine's hemodynamic effects, 595-600
role in prevention of atherosclerosis, 21-24
to reduce calcium entry and mobilization, 38
Calcium channels, mibefradil effects on receptor operated calcium channels, 815-820
Calcium entry blockers
coadministration with ACE inhibitors, 525-527
felodipine for cardiovascular disorders, 657-661
Calcium ionophore A23187, 59, 60, 510, 511
Calcium ion transients, positive inotropic therapy for heart failure, 151, 153, 154, 155-156
Calmodulin, 59, 155
Calmodulin-stimulated calcium transport, 390
Captopril, 90, 92, 94-96, 98-99, 146, 296, 301
ANG II antagonists in heart failure, 697
effects on plasma endothelin-1 during thrombolysis, 359-360
furosemide dynamics and angiotensin II, 315
in SAVE trial, 504, 505
plasma digoxin level increase in elderly after withdrawal, 829-830
reducing mortality and reinfarction, 496
renal effects, 651
vascular protection, 515, 517, 519
Verapamil-Hypertension Atherosclerosis Study, 529-530
vs. perindopril, 435
with losartan in ELITE trial, 694
Carbachol, 160
Carbamazepine
electrophysiological effects of, 709-714
sinus node recovery time, 713
Carbamazepine-10,11-epoxide, 710, 711, 712
Cardiac Arrhythmia Pilot Study (CAPS), 93
Cardiac Arrhythmia Suppression Trial (CAST), 90, 147, 497-499, 614, 715
Cardiac drugs, handbook of, 464
Cardiac dysfunction, growth hormone in rats, 125, 130
Cardiac electrophysiology, carbamazepine effects in humans, 709-714
Cardiac function
beta-adrenoceptor blockers in congestive heart failure, 273-283
clentiazem and diltiazem pharmacodynamics and pharmacokinetics, 685-691
Cardiac index, 205, 207, 792, 793
elgodipine effects, 599
enalkiren, 650
nicorandil and isosorbide dinitrate and large arteries, 331, 333, 334, 335
nicorandil clinical efficacy, 230
Cardiac Insufficiency Bisoprolol Study (CIBIS), 280
Cardiac myosin-induced autoimmune myocarditis, 704
Cardiac Study, 389
Cardiomegaly, 724, 725
Cardiomyopathies, beta-adrenoceptor blockers in congestive heart failure, 273-283
Cardioprotection
conferred by opening of ATP-sensitive potassium channels, 245-254
definition, 245
nicorandil and coronary angioplasty, 257-262
nicorandil clinical efficacy, 229-235
Cardiovascular Drugs, Current (book review), 464
Cardiovascular Pharmacology and Therapeutics (book review), 171, 465
Cardioversion, 87
Carotene, 764, 765, 767-770
Carotid artery, 32, 39, 78, 79, 80
Carotid atherosclerosis, 23
Carotid endarterectomy, 24
Carotid-femoral method, 79
Carvedilol, 280
for chronic heart failure, 282
for congestive heart failure, 276, 277, 278, 279
Catecholamines, 23, 35-36, 57, 79
angiotensin II in ELITE trial, 695
beta blockade in elderly during exercise, 289, 292
celiprolol and metabolic syndrome, 301-302
escape of aldosterone production, 146
for input stimulation of platelets, 36-37, 39-40
furosemide dynamics and arginine vasopressin, 305
furosemide dynamics and angiotensin II, 315
potential to improve LV relaxation, 534
sensitivity of ACE inhibitor-treated rats, 428
Cathepsins, 31
Cation metabolism, 391-392
¹⁴C-clentiazem, 690
CD11/CD18 complex, 27
CDC-NHLBI Lipid Standardization Program, 780
¹⁴C-diltiazem, 690
Celikalim, 195, 252
Celiprolol
effects on exercise hypertensives, 133-139
for chronic heart failure, 282
metabolic syndrome and, 295-302
vs. atenolol, 454
with calcium antagonists on AV conduction, 445-456
Cell death, 744
Central nervous system, 36
cholinomimetic agent effects, 163
Cerebral artery stenosis, 31
Cerebral hemorrhage, 499
Cerebrovascular ischemic disorders, 39
Cesium, 198
CGP 29287, 648, 650
CGP 38560, 648
CGP 38 560A, 650
Chamber stiffness constant, 535, 536
Charybdotoxin, 187
Chelerythrine, 744
Chemiluminescence, 59, 60
Chemoattractants, 27, 29
Chemotactic factors, 16
Chest pain, methylergometrine-induced myocardial ischemia, 631-632
Chest radiograph congestion, 93
Chinese Captopril Trial, 89, 90
Chinese patients, metoprolol controlled-release vs. atenolol in hypertension, 401-406
Chlorthalidone, Verapamil-Hypertension Atherosclerosis Study, 529-530
Cholesterol
altering of molecular structure of the membrane lipid bilayer, 49-50
dissociation half-life of drugs from BCPC membranes, 49, 50
membrane differential effect and drug interactions, 45-53
modulation of cell plasma membrane function and pharmacology, 52
Cholesterol, total, 482
diet and antioxidant trial on atherosclerosis, 763-770

- gemfibrozil and Mediterranean diet, 347-348, 349
- Lp(a) and lipid-lowering drugs, 679, 681, 682-683
- Lp(a), apoproteins and simvastatin, 785-788
- neopterin study, 362
- Cholesterol levels, significance in clinical trials, 501
- Cholinergic drugs, 159
- Cholinergic substitution therapy, 163
- Cholesterol-to-phospholipid (C:PL mole ratio), 45, 46, 48, 49, 50, 51, 52
- Cholestyramine, Lp(a) and lipid-lowering drugs, 677-683
- Cholestyramine therapy, 61
- Chronic angina pectoris, diltiazem controlled delivery QD, 319-329
- Chronic atrial fibrillation, celiprolol treatment, 453
- Chronic heart failure, 242
- nicorandil clinical efficacy, 230
- nicorandil two-dose study not applicable, 219
- Chronic ischemic left ventricular dysfunction, 562
- Chronic obstructive pulmonary disease, 242
- Chronic renal failure, 242
- Chronic stable angina
- elgodipine's hemodynamic effects, 595-600
- nicorandil safety in long-term treatment, 237-242
- Chymotrypsin-sensitive generating enzyme (CAGE), 697
- Cibenzoline
- effect on postischemic hearts, 351-356
- intravenous, management of acute supraventricular tachyarrhythmias, 85-87
- Ciclazindol, chemical structure, 189
- Cilazapril, 80, 81, 516-517, 518
- Cimetidine, 240
- Ciprostene, 605
- Circadian variation in sudden cardiac death, 484
- Circumflex coronary blood flow, 37
- Cirrhosis, furosemide dynamics and angiotensin II, 311
- ¹⁴C-labeled phospholipid, to measure amount of membrane lost during incubation on the filter, 48
- Class I antiarrhythmic agents, 496, 501
- causing further haemodynamic deterioration, 437
- cibenzoline effect on postischemic hearts, 351-356
- morizine, 715-722
- Class III antiarrhythmic agents, 196, 197
- Claudication, intermittent, 35
- Clentiazem
- baroreflex sensitivity, 690
- pharmacodynamics and pharmacokinetics, 685-691
- Clinical trials
- exclusion criteria, 501
- treatment for survivors of acute myocardial infarction, 495-501
- Clofibrate, 498
- Clofilium, 198
- Clonidine, 555, 759
- Clopamide. *See* Brinerdin
- Clopidogrel, 31, 39, 40
- Clot retraction time, 31
- Coagulation, 25
- Coagulation cascade, 484-485
- Collagen, 32, 35, 36, 620-626, 665, 667
- myocardial, 146
- Collagenase, 16, 17
- Collagen fibers, 80-81
- Collagen synthesis, 28
- Colliquative myocytolysis, 169
- Cold-pressor test, 222
- Combination therapy
- celiprolol with calcium antagonists on AV conduction, 445-456
- for congestive heart failure and ischemic heart disease, 503-506
- nicorandil safety, 240
- vascular protective effects of ACE inhibitors and calcium antagonists, 509-520
- Compliance, 75
- Composite end points of trials, 499
- Congenital heart disease, 85
- Congenital long-QT syndromes, 198
- Congestive cardiomyopathy, 827-828
- Congestive heart failure, 10, 451
- ACE inhibitors and calcium antagonists for treatment of, 503-506
- alinidine effect, 561
- beta-adrenoceptor blockers for, 273-283
- bradykinin, 697
- cibenzoline effect on postischemic hearts, 351
- clinical trials of ACE inhibitors, 89, 90, 91
- digoxin and myocardial infarction, 609-615, 723-728
- digoxin study, 724, 727, 728
- dopexamine withdrawal study, 791-796
- d-sotalol treatment, 437
- enalkiren effect, 650, 653
- felodipine for cardiovascular disorders, 657-661
- furosemide dynamics and angiotensin II, 311
- furosemide dynamics and arginine vasopressin, 305, 308
- growth hormone effects on rats with postinfarction left ventricular dysfunction, 130
- nicorandil clinical efficacy, 230
- nicorandil long-term treatment safety, 238, 239, 242
- plasma digoxin level increase in elderly after withdrawal, 829-830
- potassium-channel openers' effects, 200
- ramipril effect on quality of life, 589-593
- risk factors for, 483
- Connective tissues, generalized abnormalities of, aortic elastic properties affected by, 76-77
- Conscious dogs, alinidine and zatebradine for myocardial infarction, 555-562
- Contraceptives, 401-402
- influencing erythrocyte concentration and transmembrane sodium and potassium fluxes, 388, 389
- Contractility, in failing human heart, 581-586
- Controlled-delivery diltiazem, antianginal efficacy and safety, 319-329
- Controlled release formulation, metoprolol, vs. once-daily atenolol for hypertension, 401-406
- Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), 145, 148, 504
- Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS-I), 89, 90
- Cooperative New Scandinavian Enalapril Survival Study (CONSENSUS-II), 89-92, 94, 95, 100, 496
- Coronary angioplasty, 235
- nicorandil effects with, 224
- nicorandil's antiischemic effects, 257-262
- Coronary arteriography, 23, 35
- Coronary artery bypass graft (CABG) surgery, 22-24, 37, 262, 739-745
- Coronary artery bypass surgery, 94, 497, 499
- Coronary artery disease (CAD), 33, 79, 85, 163, 480, 484, 485
- Diet and Antioxidant Trial on Atherosclerosis (DATA), 763-770
- elgodipine's hemodynamic effects, 595-600
- felodipine effect, 659
- hemodynamics after two doses of nicorandil, 213-219
- isosorbide dinitrate 20mg early tolerance twice daily, 339-344
- left ventricular hypertrophy and diastolic dysfunction, 533-536
- Lp(a) and lipid-lowering drugs, 677-683
- L-propionylcarnitine long-term antianginal effects, 749-753
- m7E3 Fab markedly inhibiting platelet aggregation, 665-674
- nicorandil effects, 203-210
- nicorandil role in management of vasospastic angina, 222-223, 224, 225
- nicorandil safety in long-term treatment, 237-242
- nicorandil's hemodynamic effects, 229, 232

- nicorandil two-dose study not applicable, 219
 regression and cholesterol lowering, 9
 Coronary artery disease paradox, 295
 Coronary artery spasm, 21, 147
 nicorandil clinical efficacy, 234
 nicorandil role in management of, 221-226
 Coronary artery occlusion, 23
 Coronary artery stenosis, 31
 Coronary atheroma, 480
 Coronary blood flow
 improved by Windkessel function, 76
 nicorandil effects, 203-204, 208-210
 Coronary Drug Project, 498
 Coronary flow velocity, nicorandil and coronary angioplasty, 257-262
 Coronary heart disease (CHD), 89, 99
 beta-adrenoceptor blockers for, 273-283
 methylergometrine-induced myocardial ischemia, 631-632
 potassium channel openers therapy, 200
 Coronary occlusion, severe, 37
 Coronary spasm, 56
 intracoronary application of cholinergic agonists, 159, 161, 163-164, 165
 Coronary "steal" phenomenon, 196, 605
 Cough, intractable, 145
 Cox proportional hazards regression model, 609, 612, 613, 723, 724, 727
 Coxsackie virus B-3 myocarditis, 704
 CPK (enzyme), 245
 C protein, 155
 Creatine kinase (CK), 724, 725
 release and ischemic preconditioning in rat heart, 103
 Creatine kinase system, 582
 Creatine phosphate (CP), 107, 108, 114, 491, 582-583, 585
 CP 80,794, 649
 Cromakalim, 186, 187-188, 189, 242, 262
 cardioprotection conferred by, 250, 252, 253
 effects on action potential duration, 195, 196, 197, 198
 mechanical inhibition of smooth and cardiac muscle, 188
 vs. nicorandil, 230, 235
 Crossbridges, 584-585, 586
Crotalaria spectabilis, 810, 812
 Cushing syndrome, 130
 Cyanide derivatives, 248
 Cyanoguanidines, 187, 188
 Cyclic adenosine monophosphate (cAMP), 34, 37-39, 163, 482, 510, 619-621, 624-627, 773, 776
 positive inotropic therapy for heart failure, 151, 153, 155, 156
 Cyclical flow reductions (CFRs), 32, 33, 35-40
 Cyclic flow (Folts) model, 31, 32, 35, 37-40
 Cyclic guanosine monophosphate [cGMP], 14, 34, 195, 223, 229, 246, 339, 343
 elevating platelet levels, 38
 Cyclic guanosine 3',5'-monophosphate (cGMP), 510, 511, 619-621, 624-627
 Cyclic nucleotides, synergistic interaction of antiplatelet drugs, 619-628
 Cyclooxygenase (CYC), 35, 36, 510, 625
 Cysteine, 379
 Cytokine release, 147
 Cytokines, 17
 Cytosolic calcium, iloprost and internal calcium in platelets, 773-776
 Cytosolic guanylate cyclase, 14
 D'Agostino's test, 297
 Danish Verapamil Infarction Trial I (DAVIT I), 505, 526
 Danish Verapamil Infarction Trial II (DAVIT II), 505, 506, 526
 Data-dredging, 500
 DAU 5884, 161
 DAU 6202, 161
 Dazoxiben, 35
 DD-ACE genotype, 695
 Decreasing trans-gauche isomerizations, 51
 Defective endothelial-dependent dilatation, 9
 Dehydrosaponin 1, 185, 187
 Delayed afterdepolarizations (DADs), 545, 551, 561
 Delayed rectifier current, 190, 191
 Delayed sustained fibrillation, R56865 and reperfusion ischemic hearts, 545-552
 Deoxyribonucleic acid (DNA) site-specific proteins, 97
 Dephosphorylation, 190
 Depolarization, 185, 196, 392, 657-658
 Desensitization, iloprost and internal calcium in platelets, 773-776
 Diabetes, 25, 26, 55, 278
 ACE inhibitors to reduce ischemic events, 89, 99
 experimental, plasma membrane cholesterol content, 52
 Diabetes mellitus, 480, 483, 724, 727, 828
 aortic elastic properties affected by, 76-77
 isradipine metabolic effects in hypertensive patients, 459-460
 renal dysfunction and ANG II, 697
 Diabetic angiopathy, 773
 Diabetic neuropathy, 652
 Diabetics, 390, 520
 Diacylglycerol, 511-512
 pathways, 97
 Diagnoses, acute myocardial infarction, 610
 Diastolic blood pressure
 cilazapril vs. hydrochlorothiazide effect, 81
 potassium channel openers, 188
 Diastolic dysfunction, and left ventricular hypertrophy, relation to coronary heart disease, 533-536
 Diazepam, 35
 Diazoxide, 187, 188, 189, 195, 242, 363
 chemical structure, 188
 Dibutyl cyclic adenosine monophosphate (cAMP), positive inotropic therapy for heart failure, 151, 152, 153, 155, 156
 Dicrotic wave, Windkessel function, 75
 Dicyclomine, 161
 DIDS-sensitive $\text{Cl}^-/\text{HCO}_3^-$ erythrocyte anion exchanger, 379
 Diet, 525
 and antioxidant vitamins on atherosclerosis, 763-770
 gemfibrozil and Mediterranean diet, 347-350
 Diet and Antioxidant Trial on Atherosclerosis (DATA), 763-770
 Digitalis, 85, 146, 280, 792
 Digitalis derivatives, 377
 Digitalis-induced arrhythmias, 198
 Digitalis Investigators Group (DIG), of National Institute of Health, 615, 728
 Digitoxin, 614
 Digoxin, 87, 93, 240, 280, 283
 mode of death after myocardial infarction, 614-615
 myocardial infarction and, 609-615, 723-728
 plasma digoxin level increase in elderly after withdrawal, 829-830
 positive inotropic therapy for heart failure, 151, 152, 153, 155
 reacting with amiodarone, 827
 with ACE inhibitors and diuretics for LVD, 145, 148
 with d-sotalol, 439, 441
 Dihydroergocristine. *See* Brinerdin
 Dihydropyridines, 247, 445-446, 451, 454, 459-460, 525-526
 effect on potentiating effects of endothelin, 512
 first-generation, 10
 reducing mortality and reinfarction, 495-496
 second-generation, 10
 trials for congestive heart failure treatments, 504, 506
 vasoactivity, 813
 vs. elgodipine, 599, 600
 voltage-dependent blockade, 657-661
 with nicorandil, 240
 1,4-dihydropyridine (DHP), 45-46, 49, 50, 51-52
 Dihydropyridine-based calcium antagonists, 26
 1,4-dihydropyridine calcium channel antagonists, 48-49, 52, 53
 structural formulas, 46
 Dihydropyridine calcium channel blockers, 22, 24

- 1,4-dihydropyridine receptors, 52
 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS), 379
 Dilated cardiomyopathy, 582, 583, 705, 792, 793
 beta-adrenoceptor blockers for, 273, 275, 278, 279, 280
 Dilevalol, for chronic heart failure, 282
 Diltiazem, 10, 100, 261, 296, 361
 adverse effects, 418
 after acute myocardial infarction, 519
 ambulatory blood pressure monitoring of CD vs. twice-daily formulations, 799-806
 baroreflex sensitivity, 690
 cardiodepression, 445
 celiprolol with calcium antagonists on AV conduction, 445-456
 controlled delivery QD for angina pectoris, 319-329
 effect on vascular disease, 21, 22
 immediate-release TID for angina pectoris, 319-329
 in clinical trials for congestive heart failure, 503, 506
 membrane cholesterol content change effects, 45, 49
 once-daily vs. twice-daily dosage for systemic hypertension, 413-419
 pharmacodynamics and pharmacokinetics, 685-691
 postinfarct studies, 504-505
 reducing mortality and reinfarction, 495-496, 501
 sustained-release (SR), 319
 treatment-related adverse events, 328
 vascular selectivity, 658, 660, 661
 vs. elgodipine, 600
 vs. nicorandil, 232-233, 240
 vs. semotiadil, 809-813
 with aspirin, 38
 with nicorandil, 240
 with nitroglycerin, 319, 321, 322, 327, 328
 Diltiazem CD, 413-419, 799-806
 Diltiazem hydrochloride, 448
 sensitivity, 320
 Diltiazem reinfarction trial, 499
 Diltiazem SR, 413-419, 799-806
 Dimethylamiloride, 545, 551
 Dinitrophenol, 248
 Dioleoyl phosphatidylcholine membranes, 50
 4-Diphenylacetoxymethylpiperidine (4-DAMP), antagonist for muscarinic receptor subtypes, 160, 162
 chemical structure, 161
 Dipyrindamole, 31, 37-38, 742
 with aspirin, 37-38
 Disopyramide, 85, 87
 QT dispersion in response to, 573-579
 Ditekren, 647-648
 Diuretics, 92, 93, 130, 278-280, 283
 ACE inhibitors for LVD, 145, 146, 148
 digoxin and myocardial infarction, 725-726
 enzymuria and hypokalemia, 411
 furosemide dynamics and angiotensin II, 311-315
 furosemide dynamics and arginine-vasopressin, 305-309
 interaction with ACE inhibitors, 497
 loop, 147-148
 with d-sotalol, 439, 440, 441
 d,l-sotalol, 441-442
 Dobutamine
 heart failure in autoimmune myocarditis in rats, 701-706
 positive inotropic therapy for heart failure, 151-153, 155, 156
 Dofetilide, 197
 Dopexamine, withdrawal study in heart failure, 791-796
 Dopexamine hydrochloride, structural formula, 792
 Doppler, left ventricular hypertrophy and diastolic dysfunction, relation to coronary heart disease, 533-536
 Doppler ultrasound, to obtain pulse wave velocity, 78-79
 Dose titration, beta blocker practical therapeutic guidelines for congestive heart failure, 273, 278-279, 283
 Double-blind trial, enalapril vs. perindopril for mild to moderate hypertension, 431-436
 Double-blind withdrawal study, dopexamine in heart failure, 791-796
 Drug-abolished ischemia, 206
 Drug evaluation in angina pectoris (book review), 464
 Drug therapy, reducing mortality and reinfarction, 495-501
 Dry mouth, 163
 d-sotalol
 chemical structure, 438
 ventricular tachycardia and, 437-442
 Dynamics
 furosemide and angiotensin II, 311-315
 furosemide modulated by arginine vasopressin, 305-309
 Dyskinesia, regional, 204, 208, 209
 Dyslipidemia, 349, 350
 celiprolol and metabolic syndrome, 295-302
 Dyspnea, 275
 Dysrhythmias, 103
 7E3 monoclonal antibody, 31, 38-39, 40
 Fab fragment markedly inhibiting platelet aggregation, 665-674
 Early afterdepolarizations, 195, 197-198, 565
 Early tolerance, isosorbide dinitrate 20mg twice daily, 339-344
 Eccentric hypertrophy of the left ventricle, 96
 ECG Workbook: A Review and Discussion of ECG Findings and Abnormalities (book review), 835
 Echocardiogram, beta-blocker effects on exercise hypertensives, 134, 135
 Echocardiography, 57
 fosinopril vs. nifedipine effects on left ventricular hypertrophy, 141-143
 left ventricular hypertrophy and diastolic dysfunction relation to coronary heart disease, 533-536
 m-mode, 290, 291-292, 293
 nicorandil effect on regional perfusion, 203, 208-210
 to study aortic elasticity, 79
 Echo contrast medium (ECM), nicorandil effect on regional perfusion, 203, 208-210
 ECM decay half-life, 208, 209
 Ectopic atrial tachycardia, 85
 Endothelium, 13, 16, 18
 EDCF, 162
 Effective refractory period of the AV node (AV-ERP), 557, 560, 562
 Effort angina, 18, 163
 beraprost sodium effects, 601-606
 Eicosadienic acid, 47
 Ejection fraction, 275
 ELAM-1, 27
 Elastase, 17
 Elastic modulus, 75
 Elastic properties, and Windkessel function of human aorta, 73-81
 Elastic resistance, definition, 75
 Elastin, 32, 81
 Elderly
 angiotensin II antagonists in heart failure, 696
 diltiazem increased sensitivity, 418-419
 Evaluation of Losartan in the Elderly (ELITE) trial, 693-697
 excluded from clinical trials, 501
 nicorandil long-term treatment safety, 242
 Electrocardiogram (ECG)
 beta-blocker effects on exercise hypertensives, 134, 135
 cyclic flow reductions, 33, 37
 to monitor cibenzoline effect on sinus rhythm, 86
 Electrocardiography, fosinopril vs. nifedipine effects on left ventricular hypertrophy, 141, 142
 Electron density profiles, one-dimensional, 45
 Electropharmacology, carbamazepine electrophysiological effects in humans, 709-714
 Electrophysiologic testing, 827
 alinidine and zatebradine for myocardial infarction, 555, 557-558
 Elgodipine
 compared to other drugs, 599, 600

- hemodynamic effects in chronic stable angina, 595-600
 EMD 52692. *See* Bimakalim
 Enalapril, 146-147, 296, 301, 479, 696, 827-828
 ACE-inhibitor cough, 652
 adverse events, 434, 435
 in CONSENSUS trial, 504
 in SOLVD treatment trial for congestive heart failure, 503, 505
 intervention trials after myocardial infarction, 496
 quality of life assessed in SOLVD study, 593
 reducing atheroma, 527
 SOLVD trials' results, 90-95, 97-99
 systemic hemodynamic responses to, 96, 100
 vascular protection, 515, 517, 519
 vs. perindopril for mild to moderate hypertension, 431-436
 Enalaprilat, 92, 95, 696
 effect on endothelium-dependent vasodilation, 515
 intervention trials after myocardial infarction, 496
 Enalkiren
 for congestive heart failure, 650, 651
 renin inhibition, 645, 648, 650, 651
 Encainide, 497, 499
 Encephalomyocarditis, 704
 Endoperoxides, intermediary, 35
 Endoprost. *See* Iloprost
 Endothelial cells, 36, 359, 620, 696
 role in vascular protection, 509-511, 513, 515, 516
 Endothelial dysfunction
 escape of aldosterone production, 145, 147
 methylethylergometrine-induced myocardial ischemia, 631-632
 Endothelial glycocalyx, 28
 Endothelial growth-factor, 14, 27-28
 Endothelial injury, 26-27, 222-223
 Endothelial-relaxing factor, 25, 29
 Endothelin, 147, 222, 509-513, 515, 516, 518, 695
 calcium antagonists and, 511-512
 Endothelin-1, 26, 27, 29, 510, 512, 514
 angiotensin and, 515
 captopril effects during thrombolysis, 359-360
 during the thrombolysis, infarct size results, 831-832
 Endothelin-2, 832
 Endothelin-3, 832
 Endothelin converting enzyme (ECE), 510, 515
 Endothelium
 ACE inhibitors and relaxations, 513-517
 alterations of vasomotion in hypercholesterolemia, 57
 atherosclerosis and damage, 25-29
 calcium antagonists and, 28-29
 calcium antagonists and relaxations, 510-511
 exercise and, 482-483
 importance of, 14
 involvement in etiology of an atherosclerotic lesion, 26-28
 risk factors for acute myocardial infarction, 479-485
 role of, 56-57, 60
 Endothelium-dependent relaxation, 26
 Endothelium-dependent vascular relaxation
 abnormal, mechanisms underlying, 57-60
 in humans, 56-57, 60, 61
 Endothelium-derived nitric oxide (EDNO), 518
 Endothelium-derived hyperpolarizing factor (EDHF), 55, 56, 162, 515
 Endothelium-derived relaxing factor (EDRF), 9, 26, 38, 55, 56, 59-60
 angiotensin and, 513-515
 release involving M receptors, 161, 162
 End-stage heart failure, 489-492
 contractility in, 581-586
 chain of events leading to, 526
 Energy metabolism, ischemic preconditioning in rat heart, 103-114
 Environmental factors, influencing erythrocyte concentration and transmembrane sodium and potassium fluxes, 386-388, 393
 Enzymuria, brinerdin and minizide effect on, 407-411
 Epinephrine, 619-620
 plasma levels, 35, 36, 37, 39
 to reverse human platelet inhibition achieved by aspirin, 36, 38
 Epinephrine 5HT, 34
 Episodic angina, 97
 Episodic thrombosis, 9, 16
 ER 001533, 262
 Ergometrine provocation test, 234
 Ergonovine, 222, 223, 224, 631
 Ergonovine maleate, 223
 Ergot alkaloids, methylethylergometrine-induced myocardial ischemia in a premenopausal woman, 631-632
 Ergotamine, 631
 Erythrocytes, 380-383, 392
 intrinsic factors influencing concentration, 383-386
 ES-8891, 648
 E-selectin, 695
 Essential hypertension, 379-383, 385, 390-391, 392
 antihypertensive agent effects on renal enzymuria, 407-411
 atenolol vs. controlled-release metoprolol, 401-406
 diltiazem ambulatory blood pressure monitoring of CD vs. twice-daily formulations, 799-806
 enalapril vs. perindopril trial, 431-436
 erythrocyte sodium transport, 381-383
 fosinopril and nifedipine in left ventricular hypertrophy, 141-143
 potential causes, 388-389
 sodium and potassium intracellular concentrations, 380-381
 Verapamil-Hypertension Atherosclerosis Study, 529-530
 zankiren effect, 650
 Essential phospholipids, vs. nicotinic acid in hyperlipoproteinemia and IHD, 779-783
 Euglycemic clamp, celiprolol and metabolic syndrome, 295-302
 Evaluation of Losartan in the Elderly (ELITE) trial, 693-697
 Excess matrix formation, 28
 Exercise, 374, 657
 angiotensin II antagonists in heart failure, 695, 697
 beraprost sodium effects on exertional angina, 601-606
 beta-blockade in elderly, 289-293
 beta-blockers in congestive heart failure, 278
 elgodipine's hemodynamic effects in stable angina, 595-600
 endothelium and, 482-483
 escape of aldosterone production, 146
 lack of, as risk factor for acute myocardial infarction, 482-484
 L-propionylcarnitine long-term antian-ginal effects, 750, 751, 752, 753
 ramipril effect on quality of life in CHF trials, 591, 592
 stable angina with coronary artery disease, 224
 with Prinzmetal's variant angina, 222
 Exercise heart rate, metoprolol CR/ZOK vs. atenolol, 403, 404
 Exercise-induced angina, endothelial damage and, 480-481
 Exercise-induced ischemia, 196, 481
 Exercise stress testing, 163
 Exercise testing
 beta-blocker effects on exercise hypertensives, 133-139
 Bruce protocol for metoprolol CR/ZOK, 402, 403
 isosorbide dinitrate 20mg early tolerance twice daily, 340, 341, 343
 nicorandil efficacy by Bruce protocol, 230, 232
 nicorandil in normal coronary angina, 755-760
 stable angina pectoris, 14
 Exercise tolerance test (ETT), diltiazem controlled-delivery QD vs. immediate-release TID, 319-329
 Exercise treadmill test, beta-blockade in elderly, 289-293
 Exercise training, decreasing risk factor for acute myocardial infarction, 479-485

- Exertional angina, 21, 97, 230
 elgodipine effects, 596, 598
 Extrastimulus technique, 711
- Failing heart, contractility in, 581-586
 Falipamil, 555
 Family history, 525
 Fast-sodium-channel-dependent tissue, 197
 Fatty acid methyl esters, 47
 Felodipine, 296, 504
 for cardiovascular disorders, 657-661
 vascular selectivity, 658, 659, 660
 vs. elgodipine, 600
 Femoral artery, 78, 79
 Fenton reaction, 120
 Fibrin clots, 34
 Fibrinogen, 484, 665-666
 neopterin study, 362
 Fibrinogen, radioactively labeled, 27
 Fibrinolysis, 25, 349
 Fibrinolytic system and platelet effects, 98-99
 Fibrinopeptide A (FPA), beraprost sodium effects on exertional angina, 601-606
 Fibroblast growth factor, 14
 Fibronectin, 665
 Fibrosis and reactive hypertrophy, 535-536
 First International Study of Infarct Survival, 169
 FK-906, renin inhibition, 645, 648, 650, 652
 Flecainide, 85, 439, 497, 499
 Foam cells, 9-10, 14, 23, 27, 80, 480
 Folts model. *See* Cyclic flow (Folts) model
 Fosinopril, vs. nifedipine in left ventricular hypertrophy, 141-143
 Framingham equations for coronary heart disease, 459
 Framingham study, 141
 Frank Starling mechanism, 489
 FREQ procedure, 611, 724
 Friedewald's formula, 347, 679, 765, 780
 Fruit, diet and antioxidant vitamins on atherosclerosis, 763-770
 Fura-2, mibefradil effects on receptor operated calcium channels, 815-820
 Furosemide, 378-379, 827-828, 829
 angiotensin II and, 311-315
 dynamics in conscious rabbits, modulation by arginine vasopressin, 305-309
 Furosemide efficiency (FE), 312, 313
 Furosemide-sensitive sodium-potassium cotransport, 385
 Gallopamil, 600
 Gas-liquid chromatography, 47
 Gastrointestinal motility, 163
 Gemfibrozil, Mediterranean diet and, 347-350
 Gender, 525
 aortic elastic properties affected by, 76
 influencing erythrocyte concentration and transmembrane fluxes of sodium and potassium, 386
 Genetic hypertension, ACE inhibitor alteration of genetic hypertension development in rats, 421-429
 Genetics, predisposition to essential hypertension, 388-389
 Glibenclamide, 185, 187, 195, 196, 198, 262, 744
 antagonism, 189
 blocking ATP-sensitive potassium channels, 245, 247-254
 chemical structure, 189
 effects on cromakalim and nicorandil compared, 230, 234
 Global ischemia, preconditioning in rat heart, 103-114
 Glomerular filtration rate (GFR)
 furosemide dynamics and angiotensin II, 311, 312
 furosemide dynamics and arginine-vasopressin, 306-307, 308
 minizide and brinerdin effect on renal enzymuria, 408, 410, 411
 Glucose clearance rate (GCR), 297, 300, 301
 Glucose tolerance, celiprolol and metabolic syndrome, 295-302
 Glucuronic acid, 146
 Glutamic oxaloacetate transaminase (GOT), 245, 724, 725
 Glycine, 39
 Glycogen, rate of depletion, 103, 104, 105, 107, 111, 114
 Glycolysis, inhibited in hamster hearts in advanced heart failure stage, 155
 Glycoprotein IIb/IIIa inhibitors, 10
 Glycoprotein (GP)IIb/IIIa receptor, 665-669, 671-674
 G proteins, 59, 163, 274, 776
 G_i protein, 510, 511
 GpIb receptor, 36
 GpIIb-IIIa receptors, 31, 34, 35, 38-40
 Great cardiac vein oxygen saturation, 258-259
 Growth factors, 17, 25, 27, 31
 Growth hormone, effects in rats with postinfarction left ventricular dysfunction, 125-130
 Growth hormone-secreting tumors, 129-130
 Growth hormone deficiency, aortic elastic properties affected by, 76-77
 Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI-3), 90, 95
 Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI-3), 89, 464, 481, 496, 498, 501
 Guanethidine, 185
 chemical structure, 189
 Guanidines, 185
 Guanine nucleotide binding protein, 151
 inhibitory (Gi), 163
 Guanosine diphosphate (GDP), 246
 Guanosine monophosphate (GMP), 34, 755
 Guanosine triphosphate (GTP), 34
 Guanylate cyclase (GC), 34, 185-187, 223, 339, 343, 620
 Guanylyl cyclase, 511
 GUSTO, 498
- H-77, 649
 Haber-Weiss reaction, 120
 Hamsters, cardiomyopathic, positive inotropic therapy in heart failure, 151-156
³H-amlodipine, 48, 49, 50
Handbook of Cardiac Drugs (book review), 464
³H-cholesterol, 46-47
³H-diltiazem, 47, 50
 Healthy elderly individuals, beta blockade during exercise, 289-293
 Heart disease, APSIS Study, 493
 Heart failure, 55
 ACE inhibitors and calcium antagonists for treatment of, 503-506
 beta-blockers and, 495, 501
 d-sotalol and ventricular tachycardia, 437-442
 escape of aldosterone production in left ventricular dysfunction, 145-148
 growth hormone effects in rats, 125-130
 in autoimmune myocarditis in rats, 701-706
 positive inotropic therapy, 151-156
 ramipril effect on quality of life, 589-593
 Heart Outcome Prevention Evaluation (HOPE) study, 481
 Heart rate, renin inhibition effects, 649
 Hemodynamics
 ACE inhibitor alteration of genetic hypertension development in rats, 422-429
 after two doses of nicorandil, 213-219
 alinidine vs. zatebradine, 560-561
 beta-blockade in elderly during exercise, 289-293
 of beta-blockers, 274-275
 cibenzoline effect on postischemic hearts, 351-356
 clentiazem, 686-691
 diltiazem, 686-691
 diltiazem controlled-delivery QD vs. immediate-release TID, 322
 diltiazem once-daily vs. twice-daily dosage for systemic hypertension, 413-419
 dopexamine withdrawal study in heart failure, 791-796
 elgodipine's effects in stable angina, 595-600
 enalapril vs. perindopril for hypertension, 431-436
 growth hormone effects in rats with

- postinfarction left ventricular dysfunction, 125-130
- heart failure in autoimmune myocarditis in rats, 701-706
- isosorbide dinitrate 20mg early tolerance twice daily, 340-344
- isradipine metabolic effects in hypertensive patients, 459-460
- metoprolol CR/ZOK vs. atenolol, 402, 403, 404
- nicorandil and isosorbide dinitrate and large arteries, 331-336
- nicorandil clinical efficacy, 229-235
- nicorandil effects, 203, 204-208
- nicorandil safety in coronary heart disease, 237, 239
- Verapamil-Hypertension Atherosclerosis Study (VHAS), 529-530
- Hemoglobin AA, 383
- Hemorrhage, into the plaque, 40
- Henderson-Hasselbach equation, 153
- Heparin, 31, 35, 36, 146, 257, 566
- low molecular weight, 633
- Heparin sulfate, 25
- Hering-Breuer reflex in response to respiration, 453-454
- Heteroceptors, 161
- Hexahydro-sila-difenidol (HHSiD), antagonist for muscarinic receptor subtypes, 160, 161
- High-density lipoprotein (HDL), 57, 480
- diet and antioxidant trial on atherosclerosis, 765-770
- essential phospholipids vs. nicotinic acid in type IIb hyperlipoproteinemia and IHD, 779-783
- Lp(a) and lipid-lowering drugs, 677-683
- Lp(a), apoproteins, and simvastatin, 785-788
- High-density lipoprotein cholesterol (HDL-C), 80, 296, 298-300, 302, 482, 695
- gemfibrozil and Mediterranean diet, 347-348, 349
- neopterin study, 362
- sodium-lithium countertransport, 390
- High-energy phosphates (HEP), 246, 249, 253, 262, 534, 582
- ischemic preconditioning in rat heart, 104, 105, 107, 108, 109, 114
- L-propionylcarnitine, 753
- positive inotropic therapy for heart failure, 151, 153-156
- High-performance liquid chromatography, to measure cibenzoline plasma concentrations, 86
- High-pressure liquid chromatography (HPLC), 152
- Hill relationship, 584
- ³H-isradipine, 46-50
- Histamine, 696
- HIV protease, 647
- HMGCoA-reductase inhibitors, 349, 682
- ³H-nimodipine, 46-50
- Hodgkin's disease, 829
- HOE-140, 696, 697
- Hoe 694, 379
- Holter monitoring, digoxin and myocardial infarction, 609-615
- Homogamma linoleic acid, 47
- Honolulu Heart Program, 482
- ³H-thymidine, 514
- Human anti-murine antibody (HAMA), 671-672
- assay, 668
- responses to m7E3 Fab in stable coronary disease, 672, 673-674
- Human heavy chain C1 region, 39
- Human light chain constant region, 39
- Human platelets
- iloprost and internal calcium, 773-776
- mibefradil effects on receptor operated calcium channels, 815-820
- Humans, preconditioning the myocardium, 739-745
- ³H-verapamil, 46-47, 50
- Hyalin degeneration, 169
- Hyaluronidase, 16
- Hybrid molecules, 187, 190
- Hydralazine, 363
- Hydralazine/hydrochlorothiazide, alteration of genetic hypertension development in rats, 421-429
- Hydrochlorothiazide, 80, 81, 650
- enalapril vs. perindopril for hypertension, 433, 435
- seated diastolic blood pressure affected by fosinopril or nifedipine, 141, 142, 143
- Hypercholesterolemia, 15, 25-27, 80, 99, 481
- familial, 80
- familial, aortic elastic properties affected by, 76-77
- gemfibrozil and Mediterranean diet, 347-350
- impaired production and release of nitric oxide contributing to atherosclerosis, 55-61
- Lp(a), apoproteins and simvastatin, 785-788
- polygenic, 679, 680
- Hyperemia, 261
- Hyperinsulinemia, 295, 297, 298
- Hyperkalemia, 145, 148, 249
- Hyperlipidemia, 14, 18, 56, 59, 81, 501
- diet and antioxidant vitamins on atherosclerosis, 763-770
- endothelial injury, 26, 28
- Lp(a) and lipid-lowering drugs, 677-683
- type IIa, 348
- Hyperlipoproteinemia, 302
- type IIb, vs. nicotinic acid in hyperlipoproteinemia and IHD, 779-783
- Hyperplasia, 392
- Hyperpolarization, 185-186, 188, 195, 196, 223, 241, 332
- Hypertension, 14, 18, 25, 26, 85
- ACE inhibitors and vascular protection, 517
- ACE inhibitors for reduction of ischemic events, 89, 94, 96, 97, 98, 99
- aortic elastic properties affected by, 76, 81
- atenolol vs. controlled-release metoprolol, 401-406
- calcium channel blockers to prevent atherosclerosis, 21
- cation metabolism to, 391-392
- celiprolol and metabolic syndrome, 295-302
- clinical (book review), 363
- combination therapy for, 518
- enalapril vs. perindopril for mild to moderate hypertension, 431-436
- endothelial regulation of vasomotion, 55, 56
- family background as intrinsic factor, 384-385
- felodipine for cardiovascular disorders, 657-661
- ion transport abnormalities in, 389-391
- isradipine metabolic effects in noninsulin-dependent diabetes mellitus patients, 459-460
- mild, treatment of, 373-374
- muscarinic receptor antagonists for, 159, 165
- potassium-channel openers for, 195, 200
- reduced by amlodipine, 38
- renin inhibition, 645-653
- as risk factors for acute myocardial infarction, 480
- sodium metabolism alterations, 377-393
- to increase platelet activity, 31
- Hyperthyroidism, 828
- Hypertriglyceridemia, 295, 302, 349-350
- Hypertrophic cardiomyopathy, 85, 483, 792
- sudden death, 98
- Hypertrophy, 392
- Hyperventilation test, 222
- Hypoalbuminemia, furosemide effect, 311
- Hypoglycemic sulphonylureas, 247
- Hypokalemia, 146, 199, 410, 411, 438
- Hypokinesia, 741
- regional, 204, 208, 209
- Hypomagnesemia, 146, 147, 148, 565
- Hypophysectomy, 130
- Hypotension, 31, 36-37, 92, 95, 235, 278, 451
- beta-blockers and, 495
- symptomatic, ACE inhibitors with diuretics not tolerated, 145
- Hypothalamus, 392
- Hypothyroidism, amiodarone-lithium combination, 827-828
- Hypoxia, 198
- Ibuprofen, 35
- IDDM patients, 302

- Idiopathic cardiomyopathy, 696
 Idiopathic dilated cardiopathy (IDC), 98, 439
 beta-adrenoceptor blockers with congestive heart failure, 273-283
 d-sotalol, 441
 IGF-1, 126, 127
 Iliac artery, 79
 Iloprost, 31
 interaction of antiplatelet drugs and nitric oxide donors, 619-628
 and internal calcium in platelets, 773-776
 Imidazolines, 185
 Immune injury, 25, 26
 Immunoglobulin G, 673
 Improper subgroup, 499
 Incessant reciprocating tachycardia, 85
 Indomethacin, 35
 Infarct necrosis, 169
 Infarct size, 241
 decreased by nicorandil, 198
 growth hormone effects in rats with postinfarction left ventricular dysfunction, 126, 127, 129
 ischemic preconditioning in rat heart, 103, 111
 nicorandil clinical efficacy, 234, 235
 plasma endothelin during thrombolysis, 831-832
 reduced by nicorandil, 203
 reduced by potassium channel openers, 251-252, 253
 Inflammation, 13, 14, 16
 Inorganic phosphate (Pi), 245, 377-378, 582
 positive inotropic agents for heart failure, 152, 156
 Inositol phospholipids, 163
 Inositol trisphosphate, 190, 511-512
 pathways, 97
 Inositol-1,4,5-trisphosphate, 773
 Inotropic agents, 145-146
 Insulin, 23, 79
 Insulin-like growth factor-1, 14
 Insulinoma cell, 189, 190
 Insulin resistance, risk factors for acute myocardial infarction, 479, 480, 483
 Insulin resistance syndrome, 759
 Insulin sensitivity, celiprolol and metabolic syndrome, 295-302
 Insulin sensitivity index (ISI), 295, 297-302
 Interaction, amiodarone-lithium and sudden hypothyroidism, 827-828
 Interference, plasma digoxin level increase in elderly after withdrawal, 829-830
 Interleukin-1 (IL-1), 14-17, 27, 28, 479, 705
 Interleukin 1 β , 518
 Interleukin-2 (IL-2), 16, 706
 Interleukin-6, 706
 International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT), 22
 International rt-Plasminogen Activator/Streptokinase Mortality Trial, 741
 International Study of Infarct Survival (ISIS)
 1 trial, vascular mortality in, 500
 2 trial, 500
 4 trial, 89, 90, 95, 464, 496, 498
 Interstitial growth, 490
 Interval treatment, isosorbide dinitrate 20mg early tolerance twice daily, 339-344
 Intracellular acidosis, ischemic preconditioning in rat heart, 114
 Intracoronary electrocardiogram, nicorandil's antiischemic effects during coronary angioplasty, 257-258, 259, 260
 Intramural hemorrhage, 17
 Intrinsic compliance, 79
 Intrinsic sympathomimetic action (ISA), 445, 446, 454
 Intrinsic value (C_p), 79
 Inward rectifier channels, 247
 Ipratropium bromide, 164
 Iron stores, 479, 483
 Irreversible myocardial injury, 250, 251
 Irritable bowel syndrome, 164
 Ischemia/reperfusion, antioxidant vitamins and infarct reduction, 117-122
 Ischemic arrhythmias, 379
 Ischemic cardiomyopathy, 147, 277, 696
 Ischemic cascade, 533
 Ischemic coronary artery disease, nicorandil effects, 203, 204
 Ischemic dilated cardiomyopathy, 582
 Ischemic heart disease, 21, 24, 91, 99
 beta-adrenoceptor blockers with congestive heart failure, 273-283
 clinical implications of vascular selectivity, 660-661
 combination therapy for, 503-506
 vs. nicotinic acid in hyperlipoproteinemia and, 779-783
 Ischemic heart failure, 98
 Ischemic preconditioning, 260
 definition, 103
 of human myocardium, 739-745
 in rat heart, 103-114
 in rat heart, energy metabolism effect, 107
 in rat heart, energy-sparing effect, 104
 in rat heart, functional studies effect of preconditioning, 106, 110-111, 114
 in rat heart, histology, 108, 111
 in rat heart, myocardial histology, 104
 opening of ATP-sensitive potassium channels which confer cardioprotection, 245, 249-254
 Isoproterenol, 274, 448, 449, 450
 positive inotropic therapy for heart failure, 151, 152, 153, 155, 156
 Isoproterenol hydrochloride, 448
 Isosorbide dinitrate, 21, 163, 257, 829
 baroreflex receptor effect, 219
 drug tolerance, 331
 early tolerance twice daily 20mg dose, 339-344
 and nicorandil and large arteries, 331-336
 nicorandil effects on stable angina pectoris and stenosis, 224
 vs. nicorandil, 229, 231-233, 240
 Isosorbide mononitrate, 496
 Isosorbide-2-mononitrate, 340, 341, 342
 Isosorbide-5-mononitrate, 339-343
 vs. nicorandil, 231-232, 240
 with L-propionylcarnitine, 753
 Isovolumetric relaxation period (IRP), 76
 Isovolumic measurements, cibenzoline effect on postischemic hearts, 351-356
 Isradipine, 511
 cholesterol content effect, 45, 48-50, 52, 53
 metabolic effects in non-insulin-dependent diabetes mellitus hypertensive patients, 459-460
 structural formula, 46
 vascular selectivity, 657, 658, 660
 vs. elgodipine, 600
 Isradipine SR, 459-460
 JANA exponential curve stripping method, 686, 691
 50KD protein phosphorylation, 624, 628
 Ketanserin, 36, 198
 Killip class 3-4 disease, 359
 Kinetics
 furosemide dynamics and angiotensin II, 311-315
 furosemide dynamics in conscious rabbits, modulation by arginine vasopressin, 305-309
 KRN2391, 187
 L-660,863, 161
 L-689,306, 160
 chemical structure, 160
 Labetalol, 363
 for chronic heart failure, 282
 for congestive heart failure, 276
 Lactate, 245
 accumulation and ischemic preconditioning, 104, 105, 107, 114
 Lactate dehydrogenase (LDH), 245, 250, 611, 613, 724, 725, 744
 minizide effect, 407-411
 Lactose intolerance, 320, 321
 Large-conductance calcium-dependent potassium channel (BK_{Ca}), 185, 186, 187
 L-arginine, 14, 510, 513, 515
 Late-activation actigens, 9-10
 Laxatives, fiber-based, 678
 L-carnitine, 749, 753
 Left anterior descending coronary artery (LAD) angioplasty, 258, 260
 Left anterior descending coronary artery (LAD) flow artery, 258-259, 261

- Left anterior descending (LAD) coronary blood flow, 37
- Left ventricular (LV) angiographies, 204
- Left ventricular diastole, phases and determinants, 534-536
- Left ventricular dysfunction, 21, 23
- beta blockers for congestive heart failure, 279, 281
- escape of aldosterone production, 145-148
- mortality rates in select clinical trials, 90, 100
- SAVE study, 92, 96, 99
- Left ventricular ejection fraction (LVEF), 489
- d-sotalol effect, 437, 438, 439-440, 441, 442
- Left ventricular end-diastolic index (LVEDVI), 215, 216
- Left ventricular end-diastolic pressure (LVEDP), growth hormone effects in rats with postinfarction left ventricular dysfunction, 125-130
- Left ventricular end-systolic-volume index (LVESVI), 215, 216
- Left ventricular filling pressure (LVEDP), 204, 205, 206
- Left ventricular function
- cibenzoline effect on postischemic hearts, 351-356
- felodipine for cardiovascular disorders, 657-661
- heart failure in autoimmune myocarditis in rats, 701-706
- nicorandil effect, 203-210
- Left ventricular hypertrophy, 76, 147, 529, 696
- diastolic dysfunction and, relation to coronary heart disease, 533-536
- fosinopril vs. nifedipine, 141-143
- as risk factor for acute myocardial infarction, 479, 483-484, 485
- Left ventricular hypertrophy regression, beta-blocker effects on exercise hypertensives, 133-139
- Left ventricular systolic function, beta blockade in elderly during exercise, 289-293
- Lemakalim, 195
- Lesion activation, precipitators of, 16
- Leukocytes, 36
- chemotaxis of, 28
- Leukotriene B₂, 27
- Leukotriene C₄, 706
- Leukotriene D₄, 706
- Leukotriene LTB₂, 28
- Levcromakalim, 246, 247
- chemical structure, 188
- potassium channel opener effects, 185, 187-191
- Lidocaine, 709
- effect on sustained fibrillation during reperfusion, 550-551, 552
- LIFE TEST procedure, 611, 724
- Ligand-gated channels, 246
- Light microscopy, ischemic preconditioning in rat heart, 103, 105, 108, 111, 114
- Linoleic acid, 47
- Linolenic acid, 47
- Lipid-lowering agents, 9, 15
- reducing mortality and reinfarction, 495, 497, 501
- Lipid peroxidation, 28
- diet and antioxidant vitamins on atherosclerosis, 763-770
- Lipid perturbations, 98
- Lipid Research Clinic Program, 786
- Lipids, 79
- Lipophilic drugs, 45-53
- Lipoprotein a [Lp(a)]
- apoproteins and simvastatin, 785-788
- gemfibrozil and Mediterranean diet, 347-350
- lipid-lowering drugs and, 677-683
- neopterin study, 362
- Lipostabil, 779-783
- Lisinopril, 90, 296
- reducing mortality and reinfarction, 496
- vascular protection, 519
- Lithium, 379
- side effects, 828
- with amiodarone for sudden hypothyroidism, 827-828
- Liver, metabolizing ticlopidine and clopidogrel, 39
- Liver cirrhosis, 242
- L-nitroarginine methyl ester (L-NAME), 481
- Long term, L-propionylcarnitine antianginal long-term effects, 749-753
- Loop diuretics, 378
- Losartan, 517
- Evaluation of Losartan in the Elderly (ELITE) trial, 693-697
- Lovastatin, 827-828
- Lp(a) and lipid-lowering drugs, 677-683
- Low-density lipoprotein (LDL), 9-10, 14, 26-29, 57, 146, 525
- ELITE trial, 695
- essential phospholipids vs. nicotinic acid in type IIb hyperlipoproteinemia and IHD, 779-783
- iron stores and, 483
- Lp(a) and lipid-lowering drugs, 677-683
- Lp(a), apoproteins, and simvastatin, 785-788
- oxidized, 16
- risk factors for coronary artery disease, 479-481
- Low-density lipoprotein (LDL-C) cholesterol, 13, 23, 31, 80, 296, 298, 302
- DATA trial, 763, 765-770
- gemfibrozil and Mediterranean diet, 347-350
- neopterin study, 362
- Low-density lipoprotein oxidation, 23
- Low-flow ischemia, R56865 and reperfused ischemic hearts, 545-552
- LP-805, 187
- L-propionylcarnitine anti-anginal long-term effects, 749-753
- side effects, 753
- l-sotalol, chemical structure, 438
- L-type voltage-sensitive calcium channels, 29
- Lucigenin, 60
- Lucite sedimentation cells, 47
- Luminal surface membrane, 26
- Lusitropic effect, positive, 210
- Lymphocytes, 10, 13, 14, 16, 17
- Lysophosphatidylcholine (LPC), 14
- Lysosomal enzymes, 31
- Macrophages, 10, 16, 17, 27
- neopterin as marker for activity and for restenosis following PTCA, 361-362
- Magnesium, reperfusion arrhythmias and, 565-570
- Magnesium ions, 582
- Magnesium loss, escape of aldosterone production, 145, 146
- Magnetic resonance imaging, to study aortic elasticity, 79
- Magnetic resonance spectroscopy, 152
- Malondialdehyde, 765
- Mammary artery, human internal, 511-513, 515
- Manual electronic planimetry, 152
- Marfan syndrome, aortic elastic properties affected by, 76-77
- McN-A-343, 160
- chemical structure, 160
- McNemar's test, 403
- MDC trial, 280, 281
- Mean arterial pressure (MAP), celiprolol with calcium antagonists on AV conduction in dog heart, 445-456
- Mean left ventricular ERP of the normal zone (LVERP-NZ), 560-561
- Mechanisms of action, beta-adrenoceptor blockers with congestive heart failure, 273-283
- Medial thickening, semotiadil for pulmonary hypertension, 809-813
- Medigoxin, 829
- Mega-trials, 499
- Membrane biophysics, 45-53
- Membrane density, 246
- Membrane lipid bilayer electron density profiles, 51
- Membrane partition coefficient, 45-50, 52
- Membrane-stabilizing action (MSA), 446
- Membranopathy, 382
- Menstrual cycle
- hypertension, 392
- influencing erythrocyte concentration and transmembrane fluxes of sodium and potassium, 385-386, 392
- Metabolic syndrome, celiprolol and, 295-302

- Meta-iodobenzylguanidine (mIBG), 146
 Methacholine, 57, 160, 162, 223
 Methoctramine, antagonist for muscarinic receptor subtypes, 160, 161
 Metoprolol
 APSYS Study, 493
 controlled-release, vs. once-daily atenolol for hypertension, 401-406
 during exercise in elderly, 292
 effects on exercise hypertensives, 133-139
 electrophysiological effects, 660
 for chronic heart failure, 282, 283
 for congestive heart failure, 273-283
 plasma endothelin during thrombolysis, infarct size results, 831-832
 reducing mortality after reinfarction, 495
 vs. nicorandil, 232
 Metoprolol CR/ZOK, 401-406
 adverse reactions, 405
 Metoprolol In Acute Myocardial Infarction (MIAMI) Trial, 277
 Mibefradil, effects on receptor operated calcium channels, 815-820
 Microcirculation, 57
Micrococcus lysodeikticus, 408
 Microvilli, 26
 MILIS study, 615
 Mini-trials, 499
 Minizide, 759
 effect on renal enzymuria, 407-411
 Minnesota Living with Heart Failure Questionnaire, 695
 Minoxidil, 187, 199
 Minoxidil sulphate, 187, 189, 195
 chemical structure, 188
 Mitochondria, 120
 Mitogen-activating protein (MAP) kinase, 512
 Mitral valve disease, 85
 Mixed angina pectoris, nicorandil role in management of, 221-226
 Modulated state, 14
 Molsidomine, 207
 with nicorandil, 240
 Monocyte chemotactic protein-1, 14
 Monocyte chemotactic protein expression, 14
 MONICA project, 484
 Monoclonal antibodies, m7E3 Fab markedly inhibiting platelet aggregation, 665-674
 Monocyte chemotactic protein-1 (MCP-1), 16
 Monocytes, 9-10, 13, 14, 25, 27, 29
 Monocytes/macrophages, 16
 Monomeric cationic peptide (MSC-CF) (McP-1), 27
 Mononuclear cells, 17
 Montreal Heart Institute Study (MHIS), 22
 Moricizine, 497
 rate-dependent anisotropic conduction property in epicardial border zone, 715-722
 3-morpholinomethylsydnorimine (SIN-1), interaction with antiplatelet drugs, 619-628
 Mortality
 digoxin and myocardial infarction, 723-728
 hypertension treatments in Norway, 373-374
 Multicenter Diltiazem Post Infarction Trial (MDPIT), 90, 504-505, 614
 Research Group, 100
 Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS), 529
 Multilamellar membrane vesicles (MLVs), 47
 Multinucleated giant cells, 702, 703
 Multivessel disease, 204, 207, 208, 361, 741
 Muramidase (MUR), 407-408, 411
 Muscarine, 160
 Muscarinic receptor function, 59
 Muscarinic receptors
 circulation and, 159-165
 Schild regression lines pA_2 values and slopes, 162
Mycobacterium tuberculosis, 702
 Mydriasis, 163
 Myocardial blood flow, 9
 Myocardial collagen production, escape of aldosterone production, 145
 Myocardial contractility, growth hormone effects in rats, 125-130
 Myocardial contractility index, 216
 Myocardial hypertrophy, 490
 Myocardial hypoxia, 222
 Myocardial infarction (MI), 9, 13, 18, 23, 219, 222-223, 238-239
 ACE inhibitors and calcium antagonists for treatment of congestive heart failure, 503-506
 ACE levels and, 515
 alinidine experiment, 555-562
 amiloride effects on LV remodeling in rats, 823-825
 angiotensin-converting enzyme inhibitors to reduce ischemic events, 89-100
 beta blockade in elderly during exercise, 292
 cellular mechanisms, 16
 diagnostic determinants, 610
 digoxin and, 609-615, 723-728
 drugs to prevent coronary thrombosis, 31, 34-36, 39
 growth hormone effects in rats, 125-130
 moricizine effect, 715-722
 plasma endothelin during thrombolysis, infarct size results, 831-832
 postinfarction heart rupture, 169
 preconditioning of human myocardium, 739-745
 rate-dependent anisotropic conduction property and moricizine modification, 715-722
 risk factors for, 479-485
 risk reduced in SOLVD trials, 503, 504
 secondary, 37-38
 suspended, 497
 treatment for survivors learned from intervention trials, 495-501
 unstable angina and, 15-16
 zatebradine (UL-FS49) experiment, 555-562
 Myocardial ischemia, 15, 37, 96-97
 beraprost sodium effects on, 601-606
 beta-blockers in heart failure, 275-276
 cibenzoline effect on postischemic hearts, 351-356
 effort-induced, 163
 elgodipine hemodynamic effects, 596
 hypertension as risk factor for, 480
 intracoronary application of cholinergic agonists, 159, 161, 163, 165
 L-propionylcarnitine anti-anginal long-term effects, 749-753
 magnesium and reperfusion arrhythmias, 565-570
 methylergometrine-induced in premenopausal woman, 631-632
 nicorandil clinical efficacy, 229-235
 nicorandil effects on hemodynamics, 204-208
 nicorandil for management of vasospastic angina, 221-226
 nicorandil safety in long-term treatment, 237-242
 nicorandil's antiischemic effects during coronary angioplasty, 257-259, 262
 postinfarction heart rupture, 169
 potassium-channel opener effects, 197, 198-199
 prevented by verapamil, 506
 R56865 and reperfusion ischemic hearts, 545-552
 Myocardial norepinephrine release, escape of aldosterone production, 145
 Myocardial oxygen demand, 9, 15
 Myocardial oxygen supply/demand ratio, nicorandil two doses effect, 219
 Myocardial perfusion, nicorandil effects, 203-210
 Myocardial protection, preconditioning of human myocardium, 739-745
 Myocardial remodeling, ACE inhibitor therapy, 97
 Myocardial risk zone (AR), infarct reduction following acute myocardial ischemia/reperfusion, 117, 118
 Myocardium, contractility in failing heart, 581-586
 Myocyte hypertrophy, 96, 97, 825
 amiloride in infarcted rats, 823-825
 Myocytes
 beta blocker effects, 274
 cardioprotection and potassium channel openers, 245-254
 Myofilaments, 584

- Myosin, 245
 Myosin light chain, 583-584
 Myristic acid, 47
- N-acetyl-B-D-glycosaminidase (NAG),
 minizide effect, 407, 409, 410, 411
 N-acetylcysteine, 349
 Natriuresis, 391
 furosemide dynamics and angiotensin
 II, 311-315
 furosemide dynamics and arginine-
 vasopressin, 305-309
 Natriuretic sodium potassium-ATPase in-
 hibitor, 392
 Nebivolol
 for chronic heart failure, 282
 for congestive heart failure, 276
 Negative dromotropic effect, celiprolol
 with calcium antagonists on AV con-
 duction, 445-456
 Negative inotropism, cibenzoline effect
 on postischemic hearts, 351-356
 Negative lusitropy, 582
 Neomycin, 682
 Neopterin, as marker for restenosis fol-
 lowing PTCA, 361-362
 Nephropathy, 828
 5-(N-ethyl-N-isopropyl) amiloride, 379
 Neurohormonal stimulation, 489-492
 Neurohormone attenuation, 94, 97-98
 Neurohormones, attenuation by ACE in-
 hibition, 94, 97-98
 Neuropeptide Y, 222
 Neutrophils, 61, 235
 activated, 120
 New York Heart Association (NYHA)
 class I, 91, 503
 class II heart failure, 91, 503, 590, 695
 class III, 91, 282, 590
 class IV, 90, 504, 695
 Niacin, 349
 to reduce Lp(a), 682
 Nicardipine, 363
 preventing development of new coro-
 nary lesions, 21, 22
 vascular protective effects, 509, 512,
 519
 vascular selectivity, 657, 658
 vs. elgodipine, 599, 600
 vs. semotiadil, 813
 Nicorandil, 185-190, 744
 antiischemic effects during coronary an-
 gioplasty, 257-262
 chemical structure, 188
 clinical efficacy in ischemic heart dis-
 ease, 229-235
 combination therapy, 240
 effects on regional perfusion and left
 ventricular function, 203-210
 for normal coronary angina, 755-760
 for unstable angina, 229, 233-235
 hemodynamics after two doses of,
 213-219
 and isosorbide dinitrate and large ar-
 teries, 331-336
 management role for vasospastic an-
 gina, 221-226
 opening ATP-sensitive potassium chan-
 nels and conferring cardioprotection,
 245-254
 potassium-channel opener effects,
 195-200
 safety in long-term treatment of coro-
 nary heart disease, 237-242
 side effects, 224, 237-242
 vs. atenolol, 232, 233
 vs. beta-blockers, 231, 232
 vs. beta-blockers for coronary heart dis-
 ease, 237, 239
 vs. calcium antagonists, 231, 232-233
 vs. calcium antagonists for coronary
 heart disease, 237, 239
 vs. cromakalim, 230
 vs. diltiazem, 232-233, 240
 vs. isosorbide dinitrate, 229, 231-233,
 240
 vs. isosorbide-5-mononitrate, 231-232,
 240
 vs. metoprolol, 232
 vs. nifedipine, 232-233, 234, 240
 vs. nifedipine for Prinzmetal's variant
 angina, 223-224
 vs. nitrates, 231-232
 vs. nitroglycerin to reduce angina at-
 tacks, 239
 vs. propranolol, 232, 240
 Nicotinamides, 188
 Nicotinic acid, vs. essential phospholipids
 in type IIb hyperlipoproteinemia
 and IHD, 779-783
 Nifedipine, 38, 80, 99-100, 251, 296
 baroreflex receptor effect, 219
 digoxin and myocardial infarction, 726
 effect on blood flow, 203-210
 in clinical trials for congestive heart
 failure, 503, 506
 influence on dynamics of coronary ath-
 eroma, 525-526
 postinfarct studies, 504, 505
 preventing development of new coro-
 nary lesions, 21-22
 reducing mortality and reinfarction,
 495-496
 vascular protective effects, 509, 511,
 512, 514, 519
 vascular selectivity, 658, 659-661
 vs. elgodipine, 600
 vs. fosinopril in left ventricular hyper-
 trophy, 141-143
 vs. nicorandil, 232-233, 234, 240
 vs. nicorandil for Prinzmetal's variant
 angina, 223-224
 vs. semotiadil, 809-813
 with celiprolol on AV conduction,
 445-456
 with digoxin, 724
 with L-propionylcarnitine, 753
 Nimodipine, 599
 cholesterol content effect, 45, 48-49,
 50, 52, 53
 structural formula, 46
 Nisoldipine, 38, 51
 vascular selectivity, 658
 vs. elgodipine, 599
 Nitrate patches, 496
 Nitrates, 15, 80, 92, 278
 for angina, 759
 for Prinzmetal's variant angina, 221,
 222
 interaction with ACE inhibitors, 497,
 501
 isosorbide dinitrate 20mg early toler-
 ance twice daily, 339-344
 long-acting, with nicorandil, 240
 reducing mortality and reinfarction,
 495-496
 synergistic interaction of antiplatelet
 drugs, 619-628
 vs. nicorandil clinical efficacy, 231-232
 with amiodarone, 827
 with d-sotalol, 439, 441
 Nitrendipine, 80
 vascular selectivity, 658
 with aspirin, 38
 Nitric oxide (NO), 9-10, 13-15, 34, 38,
 249, 480-481, 484, 509-511, 513,
 515, 517-518
 antiplatelet drugs and synergistic inter-
 action, 622, 625, 627
 effect on elastic resistance of the
 aorta, 73
 endothelium-derived, 55-58, 60, 61
 increased degradation by superoxide
 anions, 59-60
 inhibition of release, 80
 nicorandil and ISDN and large arter-
 ies, 332
 release, and bradykinin, 696
 Nitric oxide synthase, 14-15, 55, 58, 61,
 510, 518, 696, 706
 alterations of activation by cellular sig-
 naling mechanisms, 59
 differences of expression or function,
 59
 Nitroglycerin, 10, 38, 56, 251, 262, 363,
 696
 effect on blood flow, 203-204, 207
 for long-term treatment of heart fail-
 ure, 339, 340
 L-propionylcarnitine long-term antian-
 ginal effects, 751
 patches, 38
 side effects, 203
 sublingual, 38
 vs. nicorandil's cardioprotection, 235
 vs. nicorandil to reduce angina at-
 tacks, 239
 with diltiazem, 319, 321, 322, 327, 328
 Nitroprusside, 363
 Nitrosylated bovine serum albumin
 (BSANO), 38
 No-flow ischemia, 250
 Non-effort-related angina, 32
 Non-insulin-dependent diabetes mellitus
 (NIDDM), 302

- isradipine metabolic effects in hypertensive patients, 459-460
- Nonischemic cardiomyopathy, 147
- NONLIN computer program, 306
- Non-Q-wave infarction, 496, 501, 503-505
- Nonsteroidal antiinflammatory drugs (NSAIDs), 35, 389
- Nonsustained ventricular tachycardia (NSVT), 558
- Noradrenaline, 94, 274, 281, 480, 515
- antagonism of levromakalim by antazoline, 190
- release blocked via stimulation of muscarinic receptors, 161, 162
- No-reflow phenomenon, ischemic preconditioning in rat heart, 111
- Norepinephrine, 25-26, 34, 94, 146-147, 223, 359, 392
- losartan effect on, 695
- risk factors for AMI, 485, 490-491
- sensitivity of mesenteric artery from ACE inhibitor-treated rats, 428
- vascular protection, 512, 515
- Normothermic ischemic cardiac arrest (NICA), reperfusion and, 104, 105, 107
- Norwegian Health Screening Service, 373
- Norwegian Timolol Trial, 281
- Nuclear magnetic resonance (NMR), 535
- age-related increase in elastic resistance in aorta, 76
- to assess volume changes of aorta, 78
- Nucleoside diphosphate, 190
- Nurses' Health Study, 481
- Nystatin, 379
- Obesity, 373-374, 483
- factor in beta-blocker effects on exercise hypertensives, 138
- Occlusive intraluminal thrombosis, 222
- 2-octadecylascorbic acid, 120
- Oleic acid, 47
- Omega-3 fatty acids, 349
- Once-daily dosing, diltiazem controlled delivery QD, 319-329
- One-dimensional electron density profiles, 48, 51
- One-vessel disease, 204, 207, 208
- Operative compliance of the artery wall, 79
- Optimal titration, diltiazem for systemic hypertension, 413-419
- Oral contraceptives, 401-402
- influencing erythrocyte concentration and transmembrane sodium and potassium fluxes, 388, 389
- Oral glucose tolerance test (OGTT), 295, 297-302
- Ouabain intoxication, 545
- Oxidative radical injury, infarct reduction following acute myocardial ischemia/reperfusion, 117-122
- Oxodipine, 599
- Oxygen-derived free radicals, 13, 14, 15
- Oxygen free radicals, 9, 10, 17, 479-480
- infarct reduction following acute myocardial ischemia/reperfusion, 117, 119, 120
- Oxprenolol, for chronic heart failure, 282
- Oxypurinol, 60
- P1060, 187, 189
- P1075, 187, 198
- P1188, 198
- Pacemakers, cardiac, 163, 281
- Pacing-induced arrhythmia, 85
- Pacing-induced ischemia, nicorandil effect, 213
- Pacing-induced myocardial ischemia (MIS), 203, 205, 206
- Palmitic acid, 47
- Palmitoleic acid, 47
- Pancreatic (cells, 187, 189, 190, 242, 247-248
- Paracetamol, 332
- Parachloromercuribenzenesulphonate, 379
- Parasympathetic system, muscarinic receptors and circulation, 159-165
- Parasympathomimetic drugs, synthetic, 159-165
- Parathyroid hormone, 392
- Paroxysmal arrhythmia, 85
- Paroxysmal atrioventricular (AV) junctional reentrant tachycardia, 85, 86
- Paroxysmal supraventricular tachycardia, 445
- Partition coefficients, drug/membrane, 45-48, 50, 52
- Passive transport, 378-379
- PC-NONLIN computer program, 313
- PC-NONLIN nonlinear estimation program, 686
- PD 134672, 648
- Percutaneous transluminal coronary angioplasty (PTCA), 23-24, 39, 238, 241, 254, 518
- endothelin-1 increase, 359
- neopterin as marker for restenosis following PTCA, 361-362
- nicorandil's antiischemic effects, 257-262
- plasma endothelin during thrombolysis, infarct size results, 831-832
- preconditioning the human myocardium, 742-743, 745
- single-vessel, 250
- Perfusion technique, Langendorf, 104, 105
- Pericardial fluid accumulation, 153
- Perindopril, 527
- adverse events, 435
- vs. captopril, 435
- vs. enalapril for mild to moderate hypertension, 431-436
- Peripheral atherosclerotic obliterative disease, 773
- Peripheral resistance, nicorandil, 210
- Peripheral vascular occlusions, 31
- Peripheral vascular resistance, 197
- Peroxynitrate radical (OONO[•]), 60
- Persantine-Aspirin Reinfarction (PARIS) trial, 37-38
- Pertussis toxin, 163
- (p-Fluor)-hexahydro-sila-difenidol (p-F-HHSiD)
- antagonist for muscarinic receptor subtypes, 160-162
- chemical structure, 161
- PG endoperoxides, 625
- PGI₂, 25, 26
- Pharmacodynamics, clentiazem and diltiazem, 685-691
- Pharmacokinetics, clentiazem and diltiazem, 685-691
- Pharmacology, 171
- Phenoxybenzamine, 36
- Phentolamine, 36, 185
- chemical structure, 189
- Phenylalkylamines, 50, 600
- Phenylephrine, 289, 292
- ACE inhibitor alteration of genetic hypertension development in rats, 421, 425-429
- Phenytol, 827
- Phloretin, 378, 379
- Phosphatidylinositol, 195
- Phosphocreatine (PCr), positive inotropic therapy for heart failure, 152, 153, 156
- Phosphodiesterase (PDE), 34, 37, 626
- Phosphoinositol, 163
- Phospholamban, 155
- Phospholipase C, 511-512
- pathway, 163
- Phosphoramidone, 515
- ³¹Phosphorus magnetic resonance spectroscopy, 152
- Phosphorylation potential, positive inotropic therapy for heart failure, 151, 153-156
- PHREG procedure, 611, 724
- Pinacidil, 187-190, 242
- cardioprotection conferred by, 247, 250, 252, 253
- chemical structure, 188
- for hypertension treatment, and as potassium-channel opener, 195-200
- Pindolol, 296
- for chronic heart failure, 282
- Pirenzepine
- antagonists for muscarinic receptor subtypes, 160, 161, 162, 163, 165
- chemical structures, 161
- Plaque rupture, 10, 13, 15-16, 21, 23, 40
- altered structural integrity, 16
- Plaques, 526
- Plasma catecholamines, 31
- Plasma concentrations, isosorbide dinitrate 20mg early tolerance twice daily, 339-344
- Plasma fibrinogen, 38

- Plasma renin activity (PRA), 99, 188, 645, 646, 650-651, 695
 alteration of genetic hypertension development in rats by ACE inhibitors, 422, 425, 427, 428
 digoxin study, 727
 furosemide dynamics and arginine vasopressin, 306, 307, 308
 furosemide dynamics and angiotensin II, 312-313, 314
 Plasminogen activator, 25
 Plasminogen activator inhibitor-1 (PAI-1), 98-99
 activity, beraprost sodium effects on exertional angina, 601-606
 Plasminogen activator inhibitor, 695
 Platelet activating factor (PAF), 32, 34, 36
 mibefradil effects on receptor operated calcium channels, 815-820
 Platelet aggregates, 32-34
 Platelet aggregation, 485, 619-627, 773
 APSIS Study, 493
 markedly inhibited by m7E3 Fab, 665-674
 mibefradil effects on receptor operated calcium channels, 815-820
 Platelet aggregation and adhesion, 61
 Platelet aggregometry, 31, 32, 39
 Platelet-derived growth factor (PDGF), 14, 27-29, 97, 99, 512, 514, 518
 Platelet derived growth factor-induced DNA synthesis, 696
 Platelet factor 4 (PF4), beraprost sodium effects on exertional angina, 601-606
 Platelet glycoprotein G_pIIB-IIIa fibrinogen receptor, 31, 34, 35, 38-39, 40
 Platelet inhibition, synergistic interaction of antiplatelet drugs, 619-628
 Platelet inhibitors, 31, 32, 35, 38-39
 Platelet-mediated arterial thrombosis, 31, 32, 33, 36
 Platelet-rich plasma (PRP), 620-627, 774
 m7E3 Fab antibody, 666, 667
 Polyacrylamide gel electrophoresis (PAGE), 783
 Polyethylene glycolated superoxide dismutase (PEG-SOD), 60
 Polymorphic ventricular tachycardia, 198
 Polythiazide. *See* Minizide
 Positive dromotropic effects, celiprolol with calcium antagonists on AV conduction, 448, 449, 450, 454
 Positive inotropic agents, therapy in end-stage heart failure, 151-156
 Postinfarction, beta blockers for congestive heart failure, 278, 281
 Postinfarction angina, nicorandil effects, 223
 Postinfarction heart rupture (PHR), 169
 Postischemic myocardium, cibenzoline effect, 351-356
 Post-transplant coronary vascular disease, 21
 Potassium
 aldosterone administration effect, 147
 intracellular, 34
 intrinsic factors influencing transmembrane fluxes, 383-386
 R56865 and reperfused ischemic hearts, 545-552
 sodium metabolism alterations, 377-393
 Potassium channel activator, hemodynamics after two doses of nicorandil, 213-219
 Potassium channel openers (PCOs), 262
 antiarrhythmic effects, 200
 basic pharmacodynamic features, 187
 classification, 186-187
 clinical electrophysiologic effects, 199-200
 effects in experimental arrhythmias, 197
 effects on potassium currents in single cells, mechanism of action, 189-190
 electrophysiologic effects, 195-200
 in vitro electrophysiologic effects, 196-197
 in vivo electrophysiologic effects, 197
 large arteries and, 331-336
 nicorandil clinical efficacy in ischemic heart disease, 229-235
 nicorandil role in management of vasospastic angina, 221-226
 nicorandil safety in long-term treatment of coronary heart disease, 237-242
 opening ATP-sensitive potassium channels and conferring cardioprotection, 245-254
 pharmacology of, 185-191
 potassium channel modulation, general principles, 185-186
 proarrhythmic effects, 200
 Potassium channels, subtypes and their characteristics, 186
 Potassium ion, 245
 Potassium loss, escape of aldosterone production, 145, 146
⁴²Potassium or ⁸⁶Rb efflux, 188-189
 Potassium supplements, digoxin and myocardial infarction, 725-726
 Practolol, 273
 Pravastatin, Lp(a) and lipid-lowering drugs, 677-683
 Prazosin. *See* Minizide
 Pregnancy, 401-402
 Preload, 96, 207, 210
 nicorandil clinical efficacy, 229, 230
 nicorandil effect, 224, 257
 reduced by nicorandil, 213, 214, 332
 reduction of, 38
 Premature ventricular beats, 610
 Premature ventricular contractions (PVCs), 567-568, 611, 613, 795
 d-sotalol efficacy and ventricular tachycardia, 437-442
 Premature ventricular depolarizations, 491
 Prenalterol, for chronic heart failure, 282
 Pressure-standardized distensability index, 79
 Primary prevention, APSIS Study, 493
 Prinzmetal's angina, 163-164
 Prinzmetal's variant angina pectoris, 221, 222, 223-224
 Proarrhythmia, 200
 Proarrhythmic action, 558, 561
 Proarrhythmogenic activity, d-sotalol treatment, 437, 442
 Procainamide, 439
 Programmed stimulation, alinidine and zatebradine for myocardial infarction, 555-562
 Progressive pump failure, 489
 Propafenone, 85, 439
 Proper subgroup, 499
 Propionyl-CoA conversion, 749, 753
 Propranolol
 during exercise in elderly, 289-293
 for chronic heart failure, 282
 reducing mortality after reinfarction, 495
 vs. nicorandil, 232, 240
 vs. nifedipine, to prevent atherosclerosis, 21
 with calcium antagonists for AV conduction, 446
 Prorenin, 645
 Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), 21, 23, 24
 Prospective Randomized Minirone Survival Evaluation (PROMISE), 90, 499, 614, 727
 Prostacyclin (PGI₂), 14, 25-26, 55-56, 99, 249, 620, 696
 analogues, 37, 619-628
 beraprost sodium effects on exertional angina, 601-606
 iloprost effect, 773, 776
 to prevent coronary thrombosis, 31, 34, 37
 vascular protection, 509, 511
 Prostaglandin E₁ (PGE₁), 620
 Prostaglandins, 100
 furosemide dynamics and angiotensin II, 313, 314-315
 furosemide dynamics and arginine vasopressin, 305, 306, 307, 308
 nicorandil and isosorbide dinitrate and large arteries, 332
 Prostanoids, 249
 Proteases, 16
 Protein-C, 484, 605
 Protein kinase A, 620, 626-627
 Protein kinase C, 740, 743-744
 Protein kinase G, 626-627
 Protein-S, 484
 Proteinuria, antihypertensive agent effects on renal enzymuria, 407-411

- Proteolytic enzymes, 10
 Protooncogenes, 96, 97
 Pro-vitamin A, 481
 Pseudonormalization of mitral flow, 534
 Psychological General Well-Being (PGWB) Index, 589, 590, 591, 592
 Pulmonary embolism, 239
 Pulmonary hypertension, semotiadil therapy for, 809-813
 Pulse pressure, 79
 risk factor for aortic stiffness, 77, 78
 Pulse wave velocity, 76, 77
 cilazapril vs. hydrochlorothiazide effect, 81
 Pulse wave velocity along the aorta (C_w), 78-79, 80
 Putative hyperpolarizing factor, 515
 Pyridylcyanoguanidine analogues, 198
 (-)-3-pyridyl pinacidil, 252
 Pyrimidines, 187, 188
- Quality of life
 beta-blockers for congestive heart failure, 277
 celiprolol and metabolic syndrome, 297
 ELITE trial, 694
 ramipril effect in CHF trials, 589-593
 Questionnaire, ramipril effect on quality of life in CHF trials, 589-593
 Quinaprilat, 515
 Quinidine, 85, 87, 198
 QRS complex, 85, 87
 QT_c interval, 87
 QT dispersion, in response to disopyramide, 573-579
 QT interval, 197, 199, 565
 QT dispersion in response to disopyramide, 573-579
 QT syndrome, 579
- R56865
 antidigitalis effect, 552
 reperfused ischemic guinea-pig hearts, 545-552
 R 68070, 35
 Race, influencing erythrocyte concentration of sodium and potassium, 383-384
 Radioimmunoassay, plasma digoxin level increase in elderly after withdrawal, 829-830
 Radionuclide angiography, 292-293
 RALES Mortality Trial, 145, 148
 Ramipril, 92-93, 95, 100, 481
 alteration of genetic hypertension development in rats, 421-429
 effect on quality of life in CHF trials, 589-593
 in AIRE trial, 504, 505
 intervention trials after myocardial infarction, 496
 vascular protection, 519
 Ramipril Multicenter Study, 589
 Randomized Aldactone Evaluation Study (RALES Pilot Study), 145, 148
- Rap 1B phosphorylation, synergistic interaction of antiplatelet drugs, 619, 624, 627, 628
 Rate-pressure product, 261
 nicorandil two-dose study, 215, 216, 218
 Rate-related effects, carbamazepine electrophysiological effects in humans, 709-714
- Rats
 conscious, growth hormone effect with postinfarction left ventricular dysfunction, 125-130
 ischemic preconditioning, 103-114
 Raynaud's phenomenon, 773
 Reactive hypertrophy and fibrosis, 535-536
 Reaven's cardiovascular metabolic syndrome, 483
 Rebound phenomenon, 795-796
 Receptor operated calcium channels (ROCC), mibefradil effects on, 815-820
 Reciprocating tachycardia, 85, 86
 Recombinant human growth hormone, effects in rats with cardiac dysfunction, 125-130
 Recombinant tissue type plasminogen activator, 359
 Recurrent ischemia, 219, 695
 Recurrent ischemic events, 22-23
 Recurrent myocardial ischemia, 147
 Redox state, 10, 15
 Reflex tachycardia, 185, 219, 445, 451, 645
 compensatory, 188
 following clentiazem or diltiazem, 687, 688
 Refractoriness
 carbamazepine, 709-714
 moricizine, 716, 717-718, 722
 Refractoriness of the infarction zone (LVERP-IZ), 560
 Regional myocardial blood flow (RMBF), infarct reduction following acute myocardial ischemia/reperfusion, 118-119
 Regional perfusion, nicorandil effect, 203-210
 Regional wall motion (RWM), nicorandil effects, 203, 204-208
 Regression, fosinopril vs. nifedipine in left ventricular hypertrophy, 141-143
 Reinfarction, 22-23
 digoxin and, 612, 727, 728
 verapamil effect, 505
 Reinfarction rate, 10
 Remikiren, renin inhibition, 645, 648, 650
 Remodeling, amiloride in infarcted rats, 823-825
 Renal clearance
 furosemide dynamics and angiotensin II, 311-315
 furosemide dynamics and arginine-vasopressin, 305-309
 Renal damage, antihypertensive agent effects on renal enzymuria, 407-411
 Renal dysfunction, progressive, 145
 Renal failure, advanced, aortic elastic properties affected by, 76-77
 Renal function
 ACE inhibitors effect, 520
 ANG II antagonists in heart failure, 696, 697
 Renal hemodynamics, renin inhibition and uptake, 650, 651, 653
 Renal transplantation, 391
 Renin, 79, 645-653
 Renin-angiotensin, furosemide dynamics and arginine-vasopressin, 305
 Renin angiotensin-aldosterone system (RAAS), 147, 527
 enalapril vs. perindopril for hypertension, 431
 renin inhibition, 645-653
 Renin-angiotensin system, 99, 482, 483, 490, 491
 ACE inhibitor effects, 509, 513-514, 519
 fosinopril vs. nifedipine effects on left ventricular hypertrophy, 143
 furosemide dynamics and angiotensin, 311
 Renin inhibition, 645-653
 substrate analog inhibitors, 647-648
 Renin inhibitory peptide (RIP), 647
 Reocclusion, 34
 Reperfusion, 23
 captopril effect on endothelin-1, 360
 ischemic preconditioning in rat heart, 103-114
 magnesium and reperfusion arrhythmias, 565-570
 nicorandil and aprikalim accelerating recovery at, 245-254
 nicorandil clinical efficacy, 234, 235
 R56865 and reperfused ischemic hearts, 545-552
 Reperfusion arrhythmia, 249, 252, 261, 379, 527, 547, 562
 aggravated by nicorandil, 241
 magnesium effect, 565-570
 Reperfusion-induced ventricular fibrillation, magnesium and reperfusion arrhythmias, 565-570
 Reperfusion injury, 169
 infarct reduction following acute myocardial ischemia/reperfusion, 117-122
 nicorandil's antiischemic effects during coronary angioplasty, 257, 261, 262
 potassium-channel opener effects, 197, 198-199
 Repolarization, 195, 197-200, 562
 aprikalim effect, 251
 carbamazepine electrophysiological effects in humans, 709-714

- Reproducibility, QT dispersion in response to disopyramide, 573-579
- Reserpine. *See* Brinerdin
- Resistance arterioles, vascular protective effects of ACE inhibitors and calcium antagonists, 509-520
- Rest angina, 225
- Restenosis
definition, 361
neopterin as marker for restenosis following PTCA, 361-362
- RGD peptide
sequence, 39
synthetic, 39
- Rheumatoid arthritis, 16
- Ribonucleic acid (RNA) polymerase, 97
- Rifampicin, 240
- Right atrial trabeculae, 743
- Right ventricular hypertrophy, semotiadil for pulmonary hypertension, 809-813
- Risk factors
endothelium involvement, 26
for acute myocardial infarction, 479-485
- Ritanserlin, 36
- Ro 40-5967. *See* Mibefradil
- Ro 42-5892, 648
- RP49356, 187
- RP52891. *See* Aprikalim
- rTPA, 498
- Rubidium, 379, 387
- Running-down phenomenon, 248
- Rupture, 500
- (R)-WAL 2014, chemical structure, 160
- RWJ 29009, 195
- Ryanodine calcium release channel, 583
- S6 kinase, 512
- Safety, nicorandil long-term treatment of coronary heart disease, 237-242
- Sarcolemma, 155
- Sarcoplasmic calcium uptake, 534
- Sarcoplasmic reticulum, 155, 512, 534, 551-552
stimulation of calcium uptake, 583
- SAS System software program, 801
- Saturated fat intake, 525
- SCA-40, 187
- Scandinavian Simvastatin Survival Study (4S), 497
- Schild regression lines, 162
- SDZ-ENS 163, chemical structure, 160
- SDZ ENZ 163, 160
- Seated diastolic blood pressure (SDBP), fosinopril vs. nifedipine effect on regression of left ventricular hypertrophy, 141-143
- Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT), 100, 609-610, 612, 614, 615, 724, 728 study group, 504
- Secondary Prevention Israeli Nifedipine Trial (SPRINT-2), 99-100
- Sematiide, 198
- Semotiadil, for pulmonary hypertension, 809-813
- Septic shock, 239
- Serotonin, 15, 147, 512, 625
platelet-input stimulation, 32, 34, 35, 36
- Serotonin receptor blockers, 31, 32, 35
- Serum high density lipoprotein cholesterol (HDL-C), escape of aldosterone production, 145, 147
- Serum lipids, 23
celiprolol and metabolic syndrome, 295-302
- Severe bradycardia, beta-blockers and, 495
- Severe Heart Failure Questionnaire (QLQ-SHF), 589, 590, 591, 592
- SG-75. *See* Nicorandil
- S₃ gallop with persistent tachycardia, 93
- Shear forces, 31, 35, 36
- Shear stress, 57, 490, 484, 510
- Sickle cell trait, 383
- Sickness Impact Profile, 695
- Sick sinus syndrome, 199, 241
- Silent ischemia, 34, 248
- Simvastatin, 497
Lp(a) and apoproteins, 785-788
- SIN-1. *See* 3-morpholino-sydnominine
- Singlet oxygen, 122
- Sinus node recovery time (SNRT), 164
- Sinus rhythm, 197, 204
restoration of, 85-86, 87
- Sinus tachycardia, 795, 796
- Sleep Dysfunction Scale, 589, 590, 591
- Small-angle x-ray diffraction, 45, 47, 48
- Small coronary arteries, nicorandil in normal coronary angina, 755-760
- Smoking, 290, 373-374, 415, 417, 525, 534, 710
ambulatory blood pressure monitoring of diltiazem, 802
as atherosclerosis risk factor, 18, 25-26, 31, 81
CHD risk factor, 98, 99
damaging coronary vascular endothelium, 480, 482
Lp(a) and lipid-lowering drugs, 679
methylglutamine-induced myocardial ischemia, 631
nicorandil and ISDN and large arteries, 332, 333
plasma membrane cholesterol content affected by, 52
- Smooth muscle, 25, 80, 81
cell growth, 17
cell proliferation, 27
cells, 14, 23, 28, 99
delayed rectifier channel, 185
growth, 13, 14
myocytes, 45-46
- S-nitroso-acetylpenicillamine (SNAP), 517
- Sodium
aldosterone administration effect, 147
dietary, 392
dietary, and blood pressure, 389
intrinsic factors influencing transmembrane fluxes, 383-386
metabolism alterations, 377-393
passive permeability, 382-383
R56865 and reperfused ischemic hearts, 545-552
Sodium antagonist, cibenzoline effect on postischemic hearts, 351-356
Sodium-calcium exchange system, 391
Sodium citrate, 36
Sodium-H⁺ exchange blocker, amiloride in infarcted rats, 823-825
Sodium 5-hydroxydecanoate, 253
Sodium-lithium countertransport, 379, 381-382, 383, 388, 390
Sodium nitroprusside, 38, 56, 234, 363, 511, 517
interaction with antiplatelet drugs in vitro, 619-628
Sodium, potassium-ATPase pump, 377-378, 381, 384, 386-388, 391-392
Sodium-potassium cotransport, 378-379, 383, 385, 386, 388, 390
Sodium-potassium transport, 381
Sodium-proton antiport, 392
Sodium-proton exchanger, 379, 382
Sodium retention, escape of aldosterone production, 145, 146
- Sokolow index, 134
- SOLVD studies, 479, 491, 693
quality of life assessed, 593
- Sotalol, 196, 197
adverse events, 437-438
- "Sparing effect" of vitamin C on vitamin E, 120
- Sphygmometric methods, 78-79
- Spirinolactone
escape of aldosterone production in left ventricular dysfunction, 145-148
plasma digoxin level increase in elderly after withdrawal, 829-830
- Spontaneously hypertensive rats (SHR)
alteration of genetic hypertension development in rats, 421-429
angiotensin II perfusion, 515, 517
- SQ 28668, 35
- SQ30741, 517
- SR 42128, 649
- Stable angina. *See* Angina pectoris, stable
- Stenosis, 18, 35-40
- Stiffness, vascular, 73-81
- Stockholm Metoprolol Trial, 281, 495
- Stop-flow ischemia, 545, 551
- Strain-gauge techniques, 57
- Streptokinase, 497, 498, 500
- Stress, catecholamine elevation and, 39-40
- Stress-induced ischemia, 206-207
- Stress-related hormones, 26
- Stroke, 23, 31, 34, 39, 239, 242
risk factors for, 483
- Stroke index
dopexamine withdrawal study in heart failure, 794, 795

- elgodipine effect, 599
 Stroke volume, 75, 78
 Stroke volume index, enalkiren, 650
 ST segment
 adenosine triphosphate-sensitive potassium channel effects, 246, 252
 changes, 204
 changes, captopril effects on plasma endothelin-1 during thrombolysis, 359
 changes, preconditioning of human myocardium, 739-745
 depression, 163
 depression, beta-blocker effects on exercise hypertensives, 135
 depression, diltiazem, controlled-delivery QD vs. immediate-release TID, 319-329
 depression, elgodipine effect, 595-599
 depression, isosorbide dinitrate 20mg early tolerance twice daily, 339-344
 depression, L-propionylcarnitine long-term anginal effects, 749-753
 depression, nicorandil clinical efficacy, 231, 232, 233, 235
 depression, nicorandil in normal angina, 758-759
 elevation, 567, 570
 elevation, nicorandil's antiischemic effects during coronary angioplasty, 257-261
 shifts, nicorandil effects, 223, 225, 226
 Studies of Left Ventricular Dysfunction (SOLVD), 89-100
 Prevention Trial (SOLVD-Prev), 90
 Treatment Trial (SOLVD-Rx), 90, 145, 146-147
 trials, 503, 504, 505
 Stunned myocardium, 250, 251, 252, 527, 740
 infarct reduction following acute myocardial ischemia/reperfusion, 119
 ischemic preconditioning in rat heart, 111
 nicorandil clinical efficacy, 234, 235
 Subendocardial ischemia, 76
 Subgroup analysis of clinical trials, 499-500
 Substance P, 513
 Succinylcholine, 566
 Sudanophilia, 763, 765
 Sudden death, 23, 199-200, 239, 242, 281, 503, 695
 aldosterone production important factor, 146-147
 beta blockers for congestive heart failure, 277
 captopril effect in SAVE trial, 504
 digoxin and myocardial infarction, 609-615, 723-728
 drugs for prevention of thrombosis and, 32, 34-35
 d-sotalol study, 441
 events leading to end-stage heart disease, 489, 491
 prevented by verapamil, 506
 as risk factor of acute myocardial infarction, 479-485
 survivors of myocardial infarction studied, 495, 498
 syndrome, 98
 verapamil effect, 505
 Sulfapyrazone, 31, 35
 Sulindac, 35
 Sulphonylureas, 242, 247, 248, 254
 Superoxide, 480
 Superoxide anion, 15, 55, 56, 59-61, 119-120
 free radical, 198, 235
 Superoxide dismutase (SOD), 15, 56, 60, 119, 517-518
 Superoxide hydroxyl radicals, 122
 Superoxide radicals, 235
 Supraventricular arrhythmias, cibenzoline effect on postischemic hearts, 351
 Supraventricular tachycardias, 87, 241
 Supraventricular tachyarrhythmias, cibenzoline in management of, 85-87
 Surgery, 238
 preconditioning the human myocardium, 745
 Surrogate end points, 498-499
 Survival After Left Ventricular Enlargement (SAVE), 89-97, 99-100, 145, 147, 496-497, 503-505
 Suspended myocardial infarction, 497
 Sustained ischemia, ischemic preconditioning in rat heart, 103-114
 Sustained ventricular tachycardia (SVT), prevention by alinidine and zatebradine in dogs, 555-562
 Syndrome X, 759
 Systemic hypertension, diltiazem once-daily vs. twice-daily dosage, 413-419
 Systemic vascular resistance index (SVRI), nicorandil and isosorbide dinitrate and large arteries, 331, 333
 Systolic blood pressure, 79
 intravenous cibenzoline effect, 87
 left ventricular afterload, 75
 Systolic hypertension, isolated, 77
 Tachyarrhythmias, 163
 Tachycardia, 163, 273, 280, 281
 exercise-induced, 134
 potassium-channel opener effects, 197
 Tachyphylaxis, 188
 T-cell-mediated autoimmune disease, 701
 T cells, 9-10, 14, 16, 17
 Tecumseh Blood Pressure study, 77, 79
 Tedisamil, chemical structure, 189
 Telenzepine, antagonist for muscarinic receptor subtypes, 160, 161
 Template bleeding time, 31
 Tetrahydroaldosterone, 146
 Tetradotoxin, 721
 Thallium-201 emission computed tomography, 601, 602-603, 604, 605
 Thallium-201 scintigraphy, 361, 757, 759, 760
 Therapeutics, 171
 Thiazide diuretics, metabolic syndrome, 295
 Thin-layer chromatography, 47
 Thioformamides, 187, 188
 Three-vessel disease, 204, 207, 208
 Thrombin, 38, 61, 516, 665
 Thrombin-receptor activating peptide (TRAP), 619-628
 Thromboangiitis obliterans, 773
 Thrombocytopenia, 671, 673
 Thromboembolic diseases, 633
 Thrombolysis, 34, 39
 captopril effects on plasma endothelin-1 during, 359-360
 plasma endothelin dependent on infarct size, 831-832
 Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials, 740
 Thrombolysis in Myocardial Infarction (TIMI)
 II trial, 741
 IV trial, 741
 Thrombolytics, 92, 94, 497, 499
 Thrombolytic therapy, 169, 248
 Thrombomodulin, 484
 Thrombosis, 13, 14, 21
 intraarterial, 15
 Thrombotic arterial occlusion, 31, 32-34, 39
 Thromboxane, 147
 Thromboxane A₂, 15, 99, 485, 601, 625, 665
 blockers of platelet activation, 32, 34, 35, 36
 Thromboxane receptor antagonists, 35, 36
 Thromboxane synthetase inhibitors, 35, 36
 Thrombus formation, 9
 Ticlopidine, 31, 39
 Time-dependent variation, QT dispersion in response to disopyramide, 573-579
 Timolol, 280
 Tissue lactate, accumulation of, 103
 Tissue macrophages, 9-10
 Tissue plasminogen activator (tPA), 14, 484
 Tissue plasminogen activator antigen (t-PA), beraprost sodium effects on exertional angina, 601-606
 T lymphocytes, 14
 Tolbutamide, 247
 Tolerability, long-term beta-blockade, 275, 279-280
 Tomography, elastic resistance of human aorta, 73
 Torsades de pointes, 198, 565, 578
 d-sotalol treatment, 437, 438, 441, 442
 Trabeculae carneae, 582, 583
 Trandolapril, 509, 516, 517, 519, 526-527
 Transcytosis, 27
 Transesophageal echocardiography, to measure aorta, 78

- Transforming growth factor beta-1, 516, 518
- Transient ischemia, 34
- Transient risk factors, 484
- Transmural ischemia, 241
- Transplantation, 57, 96, 280, 582, 586
- Transport systems, sodium metabolism alterations, 377-393
- Treadmill stress testing (TST), 134, 135
- Treatment of angina pectoris, nicorandil role in management of vasospastic angina, 221-226
- Triazolam, 36
- Triazolobenzodiazepines, 36
- Trifascicular block, 829
- Triggered activity, 197-198
- Triggers, of myocardial infarction, 484
- Triglycerides (TG), 23, 295-296, 299-300, 679, 680-681, 683, 765-770
- gemfibrozil and Mediterranean diet, 347-348, 349
- neopterin study, 362
- Trihexyphenidyl, 161
- Troponin I, 155, 584
- Troponin T, 584
- Tumor necrosis factor (TNF), 14-17, 27, 28, 705, 706
- Tumor necrosis factor-alpha, 479
- Turbidometric method for measuring platelet activity, 31
- T-wave changes, 199
- Two-vessel disease, 204, 207
- Tyrosine kinase, 512
- U46195, 36
- U63557, 35
- Ultrasound
- elastic resistance of human aorta, 73
 - imaging, Verapamil-Hypertension Atherosclerosis Study, 529-530
 - to assess volume changes of aorta, 78
- Ultrastructure, ischemic preconditioning in rat heart, 103, 111, 112, 113, 114
- Unilamellar vesicles (ULVs), 47
- Unitary conductance, 246
- Unstable angina, 9-10, 13, 23, 222-223, 359
- angiotensin-converting enzyme inhibitors to reduce ischemic events, 89, 90, 92, 93-94
 - antioxidant vitamins for infarction pretreatment, 122
 - cellular mechanisms, 16
 - Folts model of cyclic flow reductions compared, 32-37, 39
 - myocardial infarction and, 15-16
 - nicorandil clinical efficacy, 229, 233-235
 - plasma endothelin during thrombolysis, infarct size results, 831-832
 - potassium-channel openers effects, 200
 - preconditioning the human myocardium, 744-745
 - risk reduced in SOLVD trials, 503, 504
 - vascular protection, 519
- Uterine bleeding, methylergometrine-induced myocardial ischemia, 631-632
- Valsartan, 517
- Valvular heart disease, 278
- Variable threshold angina, nicorandil as treatment for, 221, 223
- Variable threshold effort angina, 225
- Variant angina pectoris
- calcium antagonists useful, 445
 - nicorandil clinical efficacy, 229, 233
 - nicorandil effects in patients, 223
- Vasa vasorum, 73, 81
- Vascular biology in ischemic syndromes, 13-18
- Vascular cell adhesion molecule-1 (VCAM)-1, 10, 14
- Vascular diseases, aortic elastic properties affected by, 76-77
- Vascular protective effects, of ACE inhibitors and calcium antagonists, 509-520
- Vascular selectivity, felodipine for cardiovascular disorders, 657-661
- Vascular smooth muscle, 15, 56, 61
- ACE inhibitor alteration of genetic hypertension development in rats, 427-428
 - alteration of genetic hypertension development in rats, 421-429
 - cells, vascular protective effects of ACE inhibitors and calcium antagonists, 509-520
- Vascular stiffness, elastic properties and Windkessel function of the human aorta, 73-81
- Vasoactive peptides, 222
- Vasoconstricting factors, 55
- Vasoconstriction, 9, 13, 14, 15, 18
- Vasodilatation, 195-196, 261
- caused by acetylcholine, 57
- Vasodilation, endothelium-dependent, 14
- Vasodilator-Heart Failure Trial (V-HeFT-II), 145, 147
- Vasodilators, direct-acting, 145-147
- Vasodilator-stimulated phosphoprotein (VASP), 624, 627
- Vasomotor regulation, alterations in atherosclerosis, 55-61
- Vasomotor tone, 9, 14-15, 222, 223
- alterations in atherosclerosis, 55-61
 - magnesium depletion effect, 147
- Vasopressin, 360, 490, 832
- Vasospasm, 9, 13
- clinical implications, 15
 - from platelet-initiated events, 32, 34, 40
 - pathophysiology of, 15
- Vasospastic angina
- decreased by amlodipine, 38
 - nicorandil role in management of, 221-226
- Vegetables, diet and antioxidant vitamins on atherosclerosis, 763-770
- Venous compliance, nicorandil and isorbide dinitrate, 331, 335-336
- Venous occlusion plethysmography, 162
- Ventricular arrhythmias, 146-148, 278, 359, 491, 695, 828
- alinidine and zatebradine for myocardial infarction, 555-562
 - antiarrhythmic drugs to prevent reinfarction, 496-497
 - cibenzoline effect on postischemic hearts, 351
 - d-sotalol and, 437-442
 - plasma endothelin during thrombolysis, infarct size results, 831-832
 - potassium-channel openers and, 197, 199, 200
 - rate-dependent anisotropic conduction property and moricizine modification, 715-722
 - as warning of reinfarction, 498-499
- Ventricular dilation, 490
- Ventricular ectopic beats, 566, 567, 568
- Ventricular ectopy, 796
- Ventricular extrasystoles (VPB), 135
- Ventricular fibrillation, 239, 241
- beta blockers for congestive heart failure, 274, 278
 - from potassium-channel openers, 197, 199
 - magnesium and reperfusion arrhythmias, 565-570
 - R56865 and reperfused ischemic hearts, 546, 552
- Ventricular hypertrophy, escape of aldosterone production, 145, 146
- Ventricular late potentials, 557, 560
- Ventricular remodeling, 489-492
- Ventricular tachyarrhythmias
- potassium-channel openers' effects, 195, 198, 200
 - rate-dependent anisotropic conduction property and moricizine modification, 715-722
- Ventricular tachycardia (VT), 252, 491, 566
- d-sotalol and, 437-442
 - potassium-channel openers and, 200
 - R56865 inhibiting effects, 551
 - rate-dependent anisotropic conduction property and moricizine modification, 715-722
- Verapamil, 10, 38
- APISIS Study, 493
- cardiodepression, 445, 446
 - coprescription with ACE inhibitor, 527
 - effect on glucolysis in cardiomyopathic hamster hearts, 55
 - effect on sustained fibrillation during reperfusion, 550-551, 552
 - improvement of Doppler-derived LV filling curve, 534, 535
 - inhibiting platelet aggregation, 819
 - membrane cholesterol content change effects, 45, 49

- nicorandil's cardioprotection compared, 235
 nonselectivity, 658, 660, 661
 not preventing atherosclerosis, 21, 22
 postinfarct studies, 503, 505
 as preventative agent for reinfarction, 526
 reducing mortality and reinfarction, 495-496, 501
 vascular protective effects, 509-512, 514, 516-517, 519, 520
 Verapamil-Hypertension Atherosclerosis Study, 529-530
 vs. elgodipine, 600
 with an ACE inhibitor, 506
 with aspirin, 38
 with nicorandil, 240
 Verapamil-Hypertension Atherosclerosis Study (VHAS), 529-530
 Verapamil SR, 529, 530
 Veratridine intoxication, 545
 Verum stress test, 597
 Vesnarinone, 727-728
 Vessel wall properties, nicorandil and isosorbide dinitrate, 331-336
 Veterans Administration Heart Failure Trial-I (VHEFT-I), 90, 442, 491
 Veterans Administration Heart Failure Trial (second) (VHEFT-II), 89
 Viral myocarditis, 283
 Vitamin A, 764, 765, 767-770
 Vitamin C, 764, 765, 767-770
 infarct reduction following acute myocardial ischemia/reperfusion, 117-122
 plus Trolax, infarct reduction following acute myocardial ischemia/reperfusion, 117-122
 Vitamin E, 480, 481, 764, 765, 767-770
 infarct reduction following acute myocardial ischemia/reperfusion, 117
 Voltage-dependent calcium channels, 223
 Voltage-gated channels, 246, 247
 Voltage operated calcium channels, mibefradil effects on receptor operated calcium channels, 815-820
 Voltage-sensitive calcium channel (VSCC), 45
 Volume elasticity, coefficient of, 75
 von Willebrand factor (vWF), 36, 485, 665
 antigen, 480

 WAL 2014, 160
 Warfarin, 496, 827
 WARIS trial, 496
 WAY 120, 491. *See* Celikalim
 Wenckebach cycle length, 710-711
 Wenckebach point, 199, 710
 White blood cells, 380
 Whites
 erythrocyte concentration and transmembrane fluxes of sodium and potassium, 383-384, 385
 hypertension, untreated, 392
 Whole-blood impedance aggregometers, 31
 Wilcoxon Mann-Whitney test, 415
 Windkessel function
 assessment in vivo in humans, 78-79
 clinical consequences of elastic resistance increase, 77
 coronary blood flow improved, 76
 effect on peripheral arteries, 76
 general considerations of, 74-75
 of aorta, 73-81
 pathophysiology of, 77
 relaxation of left ventricle improved, 76
 Women, excluded from clinical trials, 501

 Xamoterol, for chronic heart failure, 282
 Xamoterol in Severe Heart Failure Study Group, 90
 Xanthine dehydrogenase, 119, 120
 Xanthine oxidase, 60
 X-ray, to assess volume changes of aorta, 78
 X-ray diffraction, 47, 49-50, 51

 YM-796, 160
 chemical structure, 160
 YM-21095, 648
 Yohimbine, 36

 Zamifenacine, 164
 Zankiren, renin inhibition, 645, 648-652
 Zatebradine (UL-FS 49), for myocardial infarction in dogs, 555-562
 Zofinopril, 146
 Zona glomerulosa of the adrenal gland, 146

